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The contribution of the human immunodeficiency virus (HIV) epidemic to morbidity 
and mortality in pregnancy has been well documented. Effective antiretroviral 
treatment (ART) improves maternal and newborn health as well as preventing 
mother-to-child transmission (PMTCT); yet access to ART for PMTCT in low and 
middle income countries only reached 62% (66-85%) in 2012. Of the pregnant 
women who required ART for their own health, 58% accessed treatment. Provider 
initiated HIV counseling and testing in a number of health care facilities including 
antenatal clinics, was recommended in an attempt to improve health outcomes 
within the expanding HIV epidemic. Further, screening for tuberculosis and initiation 
of isoniazid prophylaxis is advised in high risk groups. The main aim of the study was 
to explore the implementation of guidelines for the management of both 
seropositive and seronegative pregnant women as limited information is available in 
three key areas in the continuum of care for pregnant women: firstly, time to 
initiation of ART in women living with HIV; secondly, the implementation of the TB 
screening processes during pregnancy; and thirdly, follow-up (HIV) testing in 
uninfected pregnant women.  
 
Methods 
An exploratory, observational, cross sectional study design presenting both 
descriptive and analytic statistics was used. A two stage cluster sampling using a 
30X7 strategy was applied in the selection of antenatal clinics within the 
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metropolitan district. Data from records of eligible women between 32 and 36 weeks 
gestation was captured onto a data collection sheet. Demographic data and details 
of ART initiation, TB screening and repeat HIV testing practices were collected. All 
data was then entered onto a Microsoft Excel spreadsheet for importing into SPSS 
for processing and analysis. 
Measures of central tendency were used and chi squared tests and the Mann 
Whitney tests were applied for the analytic component of the study. 
 
Results 
Data was collected from records of 420 women, 210 were recorded seropositive and 
210 were recorded seronegative at initial presentation. Overall, records show 202 
women (48%) presented before 20 weeks gestation.  Nurse initiation of ART 
occurred upon diagnosis of HIV infection was documented in 97% of women; TB 
screening practices however did not appear to be consistent and differed statistically 
according to administrative authority. The offer of a repeat HIV test to those women 
who initially tested uninfected was recorded to be offered at a standard rather than 
an individualised time point. Acute seroconversion was recorded in eight women. 
Statistically significant associations between HIV status and both median gestational 
age at first antenatal contact and age (in years) as well as between administrative 
authority and TB screening practices were found.  
 
Discussion, conclusion and recommendations 
Implementation of national guidelines for the management of pregnant women does 
not appear to be consistent within or across sampled clinics. Successful integration 
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of HIV services was documented; however TB screening processes and feedback 
mechanisms following referral require strengthening. Deferment and delays in 
repeat testing in women who initially test seronegative are particularly concerning. 
Training and support of health care workers on the value of complete medical 
records for the overall management and continuity of care of a pregnant female is 
essential. Further, the benefit in implementation of national guidelines in relation to 
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Antiretroviral therapy in pregnancy is a combination of three antiretroviral drugs. 
National PMTCT antiretroviral guidelines currently recommend a fixed dose 
combination of lamivudine or emtracitabine, tenofovir and efavirenz, provided that 
there are no contra indications to any of the drugs [1].  
 
Maternal mortality: maternal deaths that occur during pregnancy, delivery or within 
42 days following delivery (in the postpartum period) [2]. 
 
 
Option A provides pregnant women with prophylaxis during pregnancy with 
zidovudine (AZT) alone and additional antiretroviral (ART) medications are provided 
during labor, delivery, and the postpartum period. Infants are also provided with 
antiretroviral medication [3].  
 
Option B provides pregnant women with triple-drug ART during pregnancy and 






Option B+ is a modification of Option B proposed by the 2010 WHO PMTCT 
recommendations   in which all HIV-infected pregnant and breastfeeding women are 
eligible for lifelong antiretroviral therapy (ART) regardless of CD4 count [3]. 
 
Preventing mother–to-child transmission (PMTCT): Preventing the transmission of 
the HI virus from mother to child during the antenatal, perinatal and postnatal 
periods [1].  
 
Re testing is the repeat HIV rapid testing offered to women who initially test 
uninfected at their first antenatal visit [1]. 
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Chapter One: Introduction 
 
1. 1 Introduction 
Globally, women account for over half of the estimated number of people living with 
human immunodeficiency virus (HIV), with the highest burden of disease concentrated 
in women in the reproductive age group [4]. The impact on maternal morbidity and 
mortality is considerable. Of the deaths that occurred in women worldwide, an 
estimated 1.5 million occurred in women of childbearing potential living with HIV [5]. 
Furthermore, vertical transmission of HIV from mother to child during pregnancy, 
labour and delivery or during breastfeeding has been identified as the primary source 
of childhood HIV infections.  
 
Antiretroviral interventions implemented during pregnancy and breastfeeding have 
impacted positively on maternal health and on vertical transmission of HIV from 
mother to child [6-11]. Access to effective antiretroviral treatment (ART) reached an 
estimated 62% (66-85%) in low and middle income countries with 58% of pregnant 
women who required ART for their own health accessing treatment [4]. Antiretroviral 
coverage for preventing mother-to-child transmission (PMTCT) expanded to 83% 
[75%-90%] within sub-Saharan Africa (SSA) with a resultant mother-to-child 
transmission (MTCT) of 7% [4].  
Antenatal care (ANC) is often the first point of contact with health services for many 
women living with HIV. Provider initiated HIV counseling and testing is currently the 
standard of care within health care facilities worldwide and is identified as a key 
objective in the South African National HIV and AIDS and STI Strategic Plan [12].  The 
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provision of HIV services within ANC simplifies access to HIV rapid testing and 
facilitates the introduction of an appropriate PMTCT intervention [3]. The guidelines 
state that first time antenatal attendees should be counselled on the benefits and 
consequences of an HIV test. Rapid HIV tests are performed and women receive post 
test counseling [1]. Women who test seronegative should be offered a repeat HIV test 
after 12 weeks and/ or between 32 and 36 weeks of gestation. It is recommended that 
women diagnosed with HIV be initiated on ART on the same day of diagnosis. 
Additional procedures at this first visit involve screening for opportunistic infections 
particularly TB and obtaining CD4 assays [1].  
 
Some of the measures of successful implementation of the national guidelines include 
known HIV status at first antenatal booking, access to ART in pregnancy, offer of a 
repeat test in seronegative women, transmission of HIV from mother-to-child and the 
impact of an appropriate intervention on maternal and newborn morbidity and 
mortality. These outcome measures are designed to assess the realisation of the 
national PMTCT guidelines and are evaluated annually in the antenatal sentinel survey 
[1].  
  
1. 2 Background 
 
The current South African national PMTCT policy has been extended beyond a purely 
PMTCT approach, rather a broader maternal and newborn health approach has been 
adopted. The four elements of this policy include primary prevention of HIV, especially 
among women of child-bearing age; integration of HIV interventions with basic 
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antenatal care, sexual and reproductive health, child and adolescent health and TB 
services; strengthening postnatal care for the mother-baby pair and provision of an 
expanded package of PMTCT services [1]. 
 
The national antenatal HIV prevalence is 29.5% (95% CI: 28.7 – 30.2) with an estimated 
prevalence of 37.4% (95% CI: 35.8 – 39.0%) in KwaZulu-Natal [13]. A number of 
districts within KwaZulu-Natal have a higher antenatal HIV prevalence than the 
national prevalence, including the eThekwini Metropolitan District with an estimated 
prevalence of 38% [13]. The HIV prevalence amongst 15 to 49 year olds living in KZN 
was 27.6% in 2012. A 10% gender difference in HIV prevalence was documented in 
this age category with a higher prevalence in females. An estimated 82.7% of pregnant 
women from KZN were tested for HIV with antenatal ART initiation occurring in 85.4% 
of those infected between 2013 and 2014. Fifty six percent of women attended 
antenatal clinics prior to 20 weeks of gestation during this time frame [13]. 
 
The recent Savings Mothers report, on maternal deaths in South Africa between 2008 
and 2010, identified HIV infection as the commonest non pregnancy related 
contributor to maternal deaths [6]. The institutional maternal mortality ratio (MMR) in 
HIV infected women was almost six fold higher than that in HIV uninfected women 
[14].  
 
Tuberculosis has been identified as one of the commonest opportunistic infections in 
women in the reproductive age group. Further TB is classified as the leading cause of 
non-obstetric related maternal deaths in South Africa [14]. Antenatal contact provides 
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the opportunity to screen for TB as early detection and treatment improves maternal 
and neonatal outcomes [15]. The intertwining of the TB and HIV epidemics in young 
women, and the individual and combined impact of TB and HIV on both maternal and 
neonatal outcomes, is striking [15-20].  
 
Implementation of the national PMTCT guidelines for the management of pregnant 
women is critical to the outcome of the mother-baby dyad. However, the extent of 
implementation of the guidelines by health care workers in the management of 
seropositive and seronegative pregnant women is largely unknown.  
 
1. 3 Problem statement 
Despite the overwhelming impact of HIV on maternal and child health globally, few 
countries have achieved the 2015 target of 90% ART coverage during pregnancy. 
Successful programmes in high income countries have attained high coverage, thus 
reducing MTCT to 1%. However, ART coverage in low and middle income countries is 
62% (66%-85%) [4]. Consequently, MTCT remains high in low income countries due to 
lack of intervention, and is estimated to be between 15 and 40% [21]. Mother to child 
transmission in South Africa has decreased from 13% in 2009 to 7% in 2012 [21]. The 
number of new HIV infections in South African children decreased by 46% between 
2009 and 2012 with an estimated 21 000 children acquiring HIV in 2012 compared to 
an estimated 38 000 in 2009 [4]. Revision and implementation of guidelines for the 





Although guidelines exist for the optimal management of women during the antenatal 
period, limited success on improved maternal outcomes and MTCT is apparent. 
Factors contributing to the partial success of the SA PMTCT programme need to be 
investigated. Information is available on certain aspects of antenatal care. However, 
inadequate information is available in three key areas in the continuum of care for 
pregnant women. These include: firstly, time to initiation of antiretroviral therapy 
(ART) following presentation at ANC in women living with HIV; secondly, the 
implementation of the TB screening processes during pregnancy; and thirdly, follow-
up (HIV) testing in uninfected pregnant women.   
1.4  Aims 
In light of what remains unknown, as discussed above, this study aimed to explore the 
implementation of the national guidelines for the management of both seropositive 
and seronegative pregnant women in antenatal care in the metropolitan district of 
eThekwini.  
 
1.5   Objectives 
Aligned with the above aim, specific study objectives were developed to assess the 
implementation of national guidelines with regard to pregnant women who at 
initiation of ANC were found to be seropositive, and with regard to those that were 
found to seronegative.  
 
The study objectives for women who were found to be HIV infected at the initiation of 
ANC were to determine: 
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 the median gestational age at diagnosis of HIV infection; 
 the median gestational age at initiation of antiretroviral treatment; 
 the distribution of CD4 counts; 
 screening practices for tuberculosis and opportunistic infections.  
 
The study objectives for women who were found to be HIV uninfected at initiation of 
ANC were to determine: 
 the median gestational age at initial and repeat HIV test; 
 the proportion who seroconvert during pregnancy.  
 
The rationale for the study was to identify potential barriers to the successful 
implementation of the national guidelines which could be addressed to improve 
maternal and newborn outcomes. Further, this exploratory component of the study 
could provide the basis for future research studies.  
 
1.6  Organisation of the dissertation 
This chapter provides an introduction and background to the problem statement, as 
well as the aims and objectives of the study. 
Chapter two contains the literature review focusing on the burden of HIV disease in 
women in the reproductive age group, the impact of HIV infection on maternal and 




Chapter three comprises a journal manuscript which will be submitted to BMC Health 
Services Research Journal, and has thus been prepared according to the guidelines to 
authors for the journal. The instructions to authors are contained in the appendices 
and the contribution of each author is defined within the manuscript. 
Chapter four is the final chapter and includes an integrative discussion, 
recommendations and limitations. 
The appendices which follow chapter 4 include the protocol submitted to the post 
graduate research committee, figures not included in the manuscript, the approvals 







Chapter Two: Literature review 
 
  
2. 1 Introduction 
 
A literature review is presented in this chapter. Section one contextualises the burden 
of HIV disease in women. Section two describes the impact of antenatal HIV infection 
on maternal and neonatal outcomes. The third section discusses the practical aspects 
of the management of seropositive pregnant women with the challenges, successes 
and evolution of the PMTCT programme, as well as the integration of HIV services into 
antenatal care in an effort to improve maternal and newborn health. The significance 
of the continuum of care for women who test HIV uninfected at their first antenatal 
visit is highlighted in the latter part of the third section.  
 
The search strategy applied to identify articles relevant to this literature review used a 
combination of keywords and terms related to HIV prevention, PMTCT, pregnancy, 
antenatal TB, impact and outcomes of HIV infection in pregnancy in the PubMed, Ovid 
and Cochrane databases, as well as publications by the South African Department of 
Health, the World Health Organisation (WHO) and the Joint United Nation Programme 
on HIV and AIDS (UNAIDS). The limiters applied to the search of electronic databases 
were for articles published in English in the last 15 years. For publications emanating 




2. 2  The burden of HIV infection in women 
 
 An estimated 35.3 million people [range 32.2–38.8 million] were living with HIV at the 
end of 2012 [4]. Sub-Saharan Africa (SSA) continues to bear the burden of disease with 
71% of the epidemic evidenced in this region. Further, despite the reported decline in 
the number of new infections, adults and children in SSA were responsible for 70% of 
incident cases [4].  Women and girls account for 58% of those living with HIV, with the 
highest burden of disease in the reproductive age group.   
 
Approximately 90% of pregnant women living with HIV reside in 22 high priority 
countries, 21 of which are located in SSA [21]. South Africa ranks fourth amongst these 
high priority countries, where the number of pregnant women living with HIV is 
estimated to be 280 000 [22]. The estimated South African national HIV antenatal 
prevalence is 29.5% (95% CI: 28.7–30.2) with an estimated prevalence of 37.4% (95% 
CI: 35.8–39.0) in KwaZulu-Natal [13]. A number of districts within KwaZulu-Natal have 
a higher HIV antenatal prevalence than the national prevalence including the 
eThekwini Metropolitan District with an estimated prevalence of 38% [13]. The peak 
of the epidemic is seen in young women between the ages of 15 and 24 years, with an 
estimated prevalence in this age group of 20.5% (95% CI 19.7-21.3). Strategies to 
improve maternal and newborn health against this backdrop, are outlined in the four 
pronged approach set out in the national guidelines for the management of HIV in 




Globally, more than 90% of childhood HIV infections are due to vertical transmission 
of the virus during pregnancy, labour and delivery or breastfeeding. In 2012, an 
estimated 3.5 million children (range 1.7 million-3.4 million) were living with HIV, 
approximately 260 000 (range 230 000–320 000) acquired HIV infection and 210 000 
(190 000-250 000) children died from AIDS-related illnesses [4].    
 
Provision of antiretroviral interventions in low and middle income countries has 
prevented an estimated 850 000 children from acquiring HIV infection between 2005 
and 2012 [22]. Clinical trials have shown a triple drug combination to be more 
efficacious than single and dual therapy when provided during pregnancy for the 
management of maternal HIV infection. Antenatal ART offered to women not eligible 
for ART for their own health, reduced MTCT rates to 4.9% and 5.4% at six months and 
one year postpartum respectively in Kenya, Burkino Faso and South Africa [6]. In 
women requiring ART for their own health, transmission rates of 4.9% four to six 
weeks post delivery [7] and 2.3% one year post delivery [8] were achieved.  Additional 
interventional strategies have extended beyond the antenatal period into the 
breastfeeding period to prolong the protection afforded to the infant. These strategies 
have lowered the MTCT rates in Kenya to 5.0%, 5.7% and 7.0% at 6, 12 and 24 months 
respectively [9]. Comparable MTCT rates were seen six months postpartum in 
Tanzania [10] and Botswana [11].  
 
In addition to the diagnosis and appropriate management of HIV infection in 
pregnancy, other efforts to limit the HIV epidemic have been mobilised. Counselling 
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and testing of couples, provision of ART to sero discordant couples [23] and extension 
of PMTCT coverage into the breastfeeding period [6,9,10] form part of these efforts. 
 
2. 3   The Impact of Antenatal HIV infection on Maternal and Neonatal 
 Outcomes 
2.3.1 Contribution of HIV infection to Maternal Mortality 
 
The impact of the HIV epidemic on maternal and neonatal mortality has been well 
documented [14,24,25]. Deaths that occurred in women of the reproductive age 
group were estimated at 3.5 million in 2010 [5]. Women living with HIV/AIDS 
accounted for 1.5 million of these deaths [5]. The UNAIDS recorded a reduction in the 
number of HIV-related deaths during pregnancy and within 42 days post delivery from 
an estimated 46 000 (23 000–93 000) deaths in 2005 to 37 000 (18 000–76 000) in 
2010 [26]. Improved access to ART coupled with the natural history of the HIV 
epidemic contributed to this decline.  
 
The fifth millennium development goal (MDG 5) is aimed at improving maternal health 
and progress towards this goal was assessed by collating data on maternal deaths 
from 181 countries [27]. A distinct difference in MMRs was observed between high 
and low income countries and in the relative contribution of HIV to maternal 
mortality. The overall MMR was estimated at 210 per 100 000 live births (170-300 per 
100 000) with the MMR in developing regions 15 times higher than in developed 
regions. Causes of death were categorised as direct or indirect, with HIV classified as 
an indirect cause.  An estimated 19 000 maternal deaths globally were as a 
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consequence of HIV infection, with 17 000 of these deaths concentrated in SSA. 
Reports from SSA also demonstrate a higher MMR in women living with HIV as 
compared to those who are HIV uninfected [28-30]. Maternal deaths only occurred in 
women living with HIV as compared to those who were not, in a multi centre study in 
Malawi, Tanzania and Zambia [28]. The MMR in HIV infected women in Uganda was 
6.2 fold (95% CI 1.98- 14.93) [30] higher than the MMR in HIV uninfected women. The 
MMR in the same categories of pregnant women in South Africa was 0.8 fold lower 
than in Uganda [29]. Detailed analysis of maternal deaths in South Africa is undertaken 
by the committee for Saving Mothers. 
 
The Saving Mothers Report is a confidential enquiry into maternal deaths in South 
Africa. The recent fifth Saving Mothers report showed an increase in the institutional 
MMR to 176.2 per 100 000 live births between 2008 and 2010 [14]. Non pregnancy 
related causes were the commonest contributor to maternal deaths with HIV infection 
diagnosed in 70.4% of deaths.  Interventions for infected women were possible 
antenatally as the diagnosis of HIV infection was made in 52% of mothers during 
pregnancy and 61% of the deaths occurred postnatally. Tuberculosis (26.9%), 
Pneumocystis jirovecci pneumonia [PCP] (13.3%) and non-specified pneumonia (26%) 
were the prevalent respiratory complications identified amongst women diagnosed 
with HIV. The recommendations for reducing maternal mortality in the fifth report are 
fundamentally the same as those in the first report [14]. Screening for and 
management of opportunistic infections (OIs) must be optimised [14,29]. Health care 
worker training, support and supervision, adequate staffing, establishment and 
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strengthening of referral pathways, access to ART and laboratory tests are some of the 
critical factors which need to be addressed [14,31,32].  
2.3.2 Impact of HIV infection on Maternal Morbidity 
 
Complications associated with maternal HIV infection include pre term labour, 
spontaneous abortions and OIs [33]. Opportunistic infections in pregnancy increase 
the risk of transmission of HIV as well as other organisms to the neonate. 
Disseminated cytomegalovirus is one of the most common OIs seen in advanced HIV 
with cytomegalovirus being the commonest transplacental infection documented in 
neonates [33]. Antepartum pneumonias due to PCP, Streptococcus pneumoniae and 
Mycobacterium tuberculosis are significant contributors to maternal morbidity and 
mortality [14,33]. Complications associated with treatment of OIs, in particular fungal 
infections, have also been documented [33]. 
 
Tuberculosis is an opportunistic infection of public health concern. The latest World 
Health Report estimated 8.6 million incident cases and 1.3 million deaths as a result of 
TB in 2012 [34]. Co-infection with HIV occurred in approximately 13% of TB cases with 
75% of the HIV infected new TB cases being concentrated in the African region [34]. 
South Africa ranked third amongst 22 high TB burden countries with an incidence of 
1003 per 100 000 [34]. In South Africa, KwaZulu-Natal is at the epicentre of both the 
TB and HIV epidemics.  
 
The HIV epidemic has shifted the burden of TB disease to women of reproductive age 
with the peak of both epidemics converging in this age group [35]. Females accounted 
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for 2.9 million of the 8.6 million incident cases of TB. Further 410 000 of the 1.3 million 
TB deaths occurred in females, 160 000 of whom were HIV co infected. The 
consequences of co-infection in pregnancy include pre term labour, maternal 
mortality [15] and an acceleration of the HIV replicative and disease processes.  
The contribution of antepartum TB to maternal and neonatal morbidity and mortality 
is evident [16-18]. Tuberculosis is also recognised as an independent risk factor for the 
vertical transmission of HIV [19,20]. Prevention of active disease is therefore critical in 
highly endemic areas of HIV and TB and recommended collaborative TB and HIV 
activities for prevention include intensified case finding, isoniazid (INH) prophylaxis 
and infection control. In 2012, only 66% of people living with HIV who presented for 
health care were screened for TB and INH initiation occurred in 520 000 (31%) new 
persons [34]. Pregnant women are considered at high risk for TB and therefore the 
expanded package of PMTCT services advises the administration of the TB symptom 
questionnaire at first antenatal contact [1]. Training of nurses to administer the TB 
symptom questionnaire within antenatal clinics improved coverage of TB screening 
and active cases of TB were detected [36,37]. 
A six month course of INH is advised upon the exclusion of TB symptoms [38]. The 
benefit of INH use in reducing active disease, the duration of prophylaxis, and the 
screening tests needed to exclude active disease remain controversial [39-41].  
Additionally there is a lack of data on the tolerance, safety, side effects, efficacy and 
levels of adherence in the pregnant population to INH as well as a lack of clarity on 
timing of INH use in relation to antiretroviral treatment. The prescription of INH is 
further influenced by health care worker concerns regarding resistance, lack of recent 
training and unfamiliarity with national guidelines [42,43]. However, the provision of 
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ART together with regular screening for TB at antenatal contact visits could potentially 
improve adverse maternal and neonatal outcomes associated with TB and HIV.  
 
2.3.3 Contribution of Maternal HIV Infection to Neonatal Morbidity and Mortality 
 
Maternal HIV infection and neonatal outcomes are closely intertwined. Gestational 
exposure to HIV can result in stillbirths, low birth weight neonates, preterm deliveries, 
and an increased rate of neonatal mortality [28,32,44]. These outcomes are more 
likely if mothers experienced a serious adverse event or had advanced disease [28,44].  
Tuberculosis predominantly affects women in the reproductive age group and 
prematurity, small for gestational age newborns, low birth weight, and perinatal death 
are associated complications [45,46]. These complications, as with maternal HIV 
infection, are more evident with advanced (maternal) disease. Maternal co-infection 
can result in fetal growth restriction, congenital TB and neonatal mortality [15]. Lastly, 
the risk of vertical transmission of HIV and TB from mother to child is increased with 
advanced untreated disease or late initiation of treatment during pregnancy. This 
impact on neonatal outcomes underscores the need for intensified antenatal TB 
screening, appropriate implementation of PMTCT and TB guidelines and timeous 
linkage to interventions for both diseases.  
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2.3.4 Social impact of maternal HIV infection 
 
The social impact of HIV infection is multifaceted. The immediate impact on 
households and family structure is the loss of a parent and/or caregiver. However, the 
number of orphans has stabilized following the establishment of the ART programme 
in South Africa as the lives of those living with HIV has been prolonged and improved. 
The overall orphanhood prevalence in South Africa is 16.9% [47] with the highest 
number of orphans concentrated in KwaZulu-Natal. This could be a reflection of the 
provincial HIV prevalence as well as the quality of services available to those 
individuals living with HIV. Child headed households have emerged following the loss 
of a parent and/ or caregiver, with the child then being responsible for the provision of 
daily needs [48]. 
 
Aside from orphanhood and the associated consequences, fear of stigma and 
disclosure remain widespread issues impacting on health seeking behaviour in SSA 
[49]. Both these factors influence attendance at maternal and child health clinics, as 
well as initiation and maintenance of the appropriate ART intervention for both 
mother and child [49,50,48].  Other factors affecting treatment access are concerns of 
gender based violence and abandonment [51].  
 
Addressing and improving the social factors impacting on access to HIV services would 





2. 4    Guidelines for the Management of HIV infection in pregnancy  
 
The management of HIV in pregnancy initially focused on a PMTCT intervention in the 
antenatal period. The guidelines have subsequently developed to incorporate a 
comprehensive maternal and newborn health service extending from the antenatal to 
the postnatal period. The historical progression of the PMTCT guidelines and its 
integration into health care systems is outlined below. 
2.4.1 Evolution of PMTCT Guidelines 
 
Programmes aimed at reducing MTCT have evolved with evidence based research and 
practice to integrate HIV prevention, care and treatment into the package of maternal, 
neonatal and child health and nutrition services. Antenatal care provides an entry 
point into health care for women living with HIV. The first step in linkage to 
appropriate care in the antenatal period is the offer of an HIV test. Provider initiated 
HIV counseling and testing was recommended in an attempt to improve access [3,52]. 
The integration of HIV services into antenatal services is aimed at expediting access to 
HIV rapid testing and initiation of ART during pregnancy.  
 
Triple ART was recommended by the World Health Organization in 2013 for all 
pregnant women for the duration of MTCT risk [53]. Women who qualify for ART for 
their own health should continue on lifelong therapy and countries with generalised 
HIV epidemics are advised to adopt this approach. Women who are not eligible for 




The decision to initiate lifelong ART in pregnancy was previously based on clinical and 
immunological staging. Women living with HIV were then assessed for Option A or 
Option B [3]. Option A recommended the use of different ART during the antenatal, 
intrapartum and postpartum periods.  Initially Option A was recommended at the 
onset of pregnancy [54], earlier initiation during the first trimester of pregnancy was 
recommended in the later guidelines [3]. The quality of evidence for this 
recommendation is low and based on observational studies which demonstrated the 
benefit of early prophylaxis in the prevention of in utero transmission of HIV. Reports 
of drug resistance [55] and virologic failure following single dose nevirapine use [56] 
prompted the addition of other ARTs to Option A [57,58]. The challenges associated 
with Option A included the changes in ART from the antenatal to the postpartum 
periods for both the patient and the health care worker (HCW) and the requirement of 
a CD4 count prior to ART initiation.  
 
In comparison, all pregnant women are initiated and maintained on a fixed drug 
combination from 14 weeks gestational age until post delivery with Option B [3]. This 
latter option is identical to the treatment used in the non pregnant population and is a 
simpler, more practical alternative for HCWs. A baseline CD4 count result prior to ART 
initiation is also not necessary and with same day initiation, an improvement in PMTCT 
coverage was anticipated.  
 
Malawi introduced Option B+ mid 2011 in an attempt to accelerate ART coverage 
during pregnancy and to decrease the incidence of HIV infection in children [59,60]. A 
seven fold increase in PMTCT coverage was documented following the introduction of 
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Option B+ [60]. This achievement resulted from the decentralization of services, 
expansion and integration of ART sites into existing antenatal services, training of 
HCWs and commitment from the Ministry of Health [60]. Seventy seven percent of 
women initiated on ART were retained in care one year later [60]. Different “models of 
care” however were used to introduce Option B+ within health care facilities in 
Malawi. The impact of the choice of model on uptake of ART and retention within the 
programme in a defined area in Malawi, recently showed difficulties in continuum of 
care postdelivery [61]. A combination of health care factors and patient factors were 
responsible for the varying retention levels. In another report looking at factors 
responsible for ‘loss to follow up’ following initiation on Option B+ in Malawi, 20% of 
women who initiated ART during pregnancy or breastfeeding missed a scheduled 
appointment and 24% were lost to follow up within the first six months [62]. Loss to 
follow up occurred more frequently in the early stages of the programme, when ART 
was introduced during pregnancy and in younger women. Education and financial 
factors were other factors identified as barriers to retention in care [62]. 
 
Other long term concerns with option B+ include cost effectiveness, suboptimal 
adherence [63] and subsequent drug resistance and adverse pregnancy outcomes 
resulting from long term exposure to ART [64]. Despite the challenges associated with 
Option B+, 13 of the 22 Global Plan priority countries had adopted this strategy by 
June 2013 [22]. Clinical outcomes and retention within care have yet to be published. 
In a meta-analysis of 51 studies with 20 153 pregnant women, adequate adherence to 
treatment was achieved in only 73.5% (95% CI 69.3–77.5%) with poorer adherence 
observed in the postpartum period [63]. An early qualitative study from Tanzania 
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regarding the acceptability of the PMTCT options, found that participants favoured 
Option B over Option A [65]. Concerns related to long term adherence and side effects 
to treatment mirrored the Malawian experience.  
 
The additional benefits associated with Option B+ are far reaching and include the 
protection for future pregnancies [66], improvement in maternal health and reduction 
in the transmission to HIV uninfected partners [67]. These advantages prompted a 
WHO programmatic update in 2012 [68] and the current consolidated guidelines of 
2013 no longer recommend Option A [53]. The updated South African PMTCT 
guidelines were based on these WHO guidelines. All HIV infected pregnant women are 
to be initiated on ART at first antenatal interaction [1] with ART to be continued 
lifelong if the (maternal) CD4 count 350 cells/mm3 and below. The duration of ART 
prophylaxis in women who have CD4 counts above this threshold is directed by infant 
feeding choice [1]. 
 
In summary, the choice of implementation of Option B or Option B+ is country 
dependent. New PMTCT policies have been adopted in a concerted effort to curb 
MTCT and achieve the MDGs four, five and six of reducing child mortality, improving 
maternal health and combating HIV, malaria and other diseases. 
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2.4.2 Integration of Guidelines into existing Programmes and The Role of Nurse 
Initiated Management of Antiretroviral Treatment 
 
Integration of PMTCT interventions into existing maternal and child health services is 
considered to be the key to successful programmes. This strategy could possibly 
expand access, improve efficiency, effectiveness and quality of health facilities. In a 
South African study, time to initiation of ART in pregnancy was reduced by median 
number of 19 days with the integration of key HIV services within antenatal facilities in 
[69]. The number of Zambian women initiating ART during pregnancy doubled with 
the integration of ART into antenatal services; however, this did not improve duration 
on ART prior to delivery [70]. 
 
Nurse initiated management of ART (NIMART) is a task shifting strategy [59] adopted 
by the South African government to address the scale up required of public sector ART 
provision.  By capacitating nurses to effectively initiate and manage stable patients on 
ART, fewer referrals and linkages to other health care facilities are required. Little has 
been written about the contribution of nurses to the antenatal sector in this regard 
[60,71]. In a comparison of time to initiation of ART prior to and following NIMART in 
five antenatal clinics in the Johannesburg Health District, a delay in ART initiation was 
found in four of the five facilities reviewed [71]. Suggested contributory factors 
include possible staff shortages and the dedication of certain clinic days to NIMART. 
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Integration of services provides a comprehensive service to patients and would impact 
on referrals and retention within the health care system. It is essential however to 
address health system factors affected by the increased workload.  
 
2.4.3 Guidelines for dealing with pregnant women who test HIV uninfected at first 
antenatal visit 
 
Pregnant women who test HIV uninfected at their first antenatal visit also require 
intensive follow up care. The World Health Organisation Guidelines of 2007 [63] as 
well as the current South African guidelines [1], advocate the re testing of this 
category of women 12 weeks after the initial test and/or between 32 and 36 weeks 
gestation. 
 
Reports of acute seroconversion later in pregnancy and its contribution to the 
paediatric burden of disease are the basis for global concern. The increased risk of 
vertical transmission is linked to the viraemia associated with acute seroconversion 
[72,73]. In a mathematical model developed to estimate changes in MTCT in South 
Africa over time, it was calculated that by 2014, 34% (95% CI: 29%-39%) of MTCT 
would be due to seroconversion in pregnant women following their first antenatal 
booking and during breast feeding [74]. Additionally risky sexual behaviour following 
an initial seronegative result has been documented [72,73].  
 
The risk of incident HIV in pregnancy remains controversial. Some reports from SSA 
reflect significant risk of incident HIV in pregnancy [75-77] with the incident rate per 
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100 person years ranging from 2.3 cases [75] to 10.7 cases [77]. Further, incidence was 
higher during pregnancy than non pregnancy [76,77]. The transmission of HIV from 
mother-to-child was not assessed in these three studies [75-77].There have been 
reports on the other hand, that show no increase in HIV risk during pregnancy [78,79]. 
Regardless of the risk, counseling messages should encompass HIV prevention 
strategies to remain seronegative. 
 
International focus has shifted from a purely treatment based approach to include the 
prevention of incident HIV. Strategies aimed at protecting young women from HIV 
infection include the use of ART prior to and following high-risk exposure, vaginal 
microbicides, female condoms and medical male circumcision.   
2.5  Challenges and Successes of Maternal and Newborn Health 
programmes 
 
Despite the overwhelming impact of HIV on maternal and child health globally, few 
countries have achieved the 2015 target of 90% coverage of ART for PMTCT [4]. 
Successful PMTCT programmes in high income countries have reduced the MTCT rate 
to less than 1%. In the absence of a PMTCT intervention however, MTCT remains high 
in low income countries at 15% to 40% [4,80]. Access to effective ART for PMTCT in 
low and middle income countries reached 62% (66%-85%) in 2012 with only 58% of 
pregnant women who required ART for their own health accessing treatment [4]. 
Within SSA, antiretroviral coverage for PMTCT expanded to 83% (75%-90%) with a 
resultant MTCT rate of 7%. Botswana, Namibia, Zambia and Ghana achieved the 90% 
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coverage target whilst South Africa, Mozambique, Swaziland and Zimbabwe have 
made moderate progress towards this goal. The current concern is the deterioration in 
coverage detected in some countries [4].  
 
Health system and patient related factors contribute to the successes and challenges 
associated with the PMTCT programme. Improved ART coverage and increased 
numbers of women accessing HIV testing reflect successes achieved by the 
programme [1]. Health system factors contributing to poor coverage include attrition 
along the PMTCT pathway, referral to ART clinics for initiation of ART, accessibility and 
availability of CD4 assays, complexity of national guidelines and a lack of HCW 
understanding of national guidelines [48,81]. Contributory patient factors include lack 
of knowledge, fear of stigma and non- disclosure [48,81]. Several high priority 
countries addressed some of these factors resulting in a 50% reduction in the 
estimated number of new infections among children. South Africa has made moderate 
strides towards achieving this latter goal.  
 
The 90% target for PMTCT coverage has been achieved by some countries with a 
subsequent reduction in the number of incident cases in children. Comprehensive 
coverage globally however still needs to be achieved with renewed and concerted 





2.6 Summary of literature review 
 
The literature review has highlighted the contribution of HIV and its associated 
opportunistic infections on both maternal and neonatal outcomes.  Guidelines for the 
management of pregnant women have evolved based on evidence based research and 
have been implemented worldwide to reduce vertical transmission of HIV from 
mother to child. Achievement of 90% PMTCT coverage has been achieved in some 
countries, others continue to strive towards this goal. An improvement in access to 
HIV services has been documented in South Africa. Assessment of the implementation 
of national guidelines could further identify gaps in available information and 
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The human immunodeficiency virus (HIV) epidemic has contributed significantly to 
maternal, newborn and childhood morbidity and mortality. Guidelines for the 
management of pregnant women form a basis for the care within health care systems. 
Few studies have evaluated the adequacy of the quality of care in primary health care 
facilities in South Africa. This study explored the implementation of national PMTCT 
and TB guidelines by health care workers in the management of seropositive and 
seronegative pregnant women. Initiation of ART and tuberculosis screening process in 
seropositive pregnant women and follow-up HIV rapid testing in seronegative pregnant 
women were assessed.   
 
Methods 
An exploratory, observational, cross sectional study design presenting both descriptive 
and analytic statistics was used. Thirty antenatal clinics within the metropolitan district 
were sampled using a 30x7 strategy and eligible women between 32 and 36 weeks 
gestation were enrolled. Variables of interest were captured onto a data collection sheet, 
entered onto a Microsoft Excel spreadsheet and imported into SPSS for processing and 




Data was collected from records of 420 women, 210 were seropositive and 210 
seronegative.  Overall, 48.1% of women presented before 20 weeks gestation. Nurse 
initiation of ART upon diagnosis of HIV infection was documented in 96% of women; 
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TB screening practices however did not appear to be consistent and differed statistically 
according to administrative authority. Repeat HIV testing in women who were initially 
seronegative occurred at a standardised rather than an individualised time point. 
Seroconversion was recorded in eight women (4.5%). 
 
Conclusion and interpretation and recommendations 
Implementation of national guidelines for the management of pregnant women does not 
appear to be consistent within or across sampled clinics. Successful integration of HIV 
services was documented; however TB screening processes and feedback mechanisms 
following referral require strengthening. Records of deferment and delays in repeat 
testing in women who initially test seronegative are particularly concerning. Training 
and support of health care workers on the value of complete medical records for the 
overall management and continuity of care of pregnant women is essential. Further, the 















Sub-Saharan Africa bears the brunt of the human immunodeficiency virus (HIV) 
epidemic with 71% of people infected with HIV located in this region [1]. Women 
account for 58% of those living with HIV in 2012, with the highest burden of disease in 
the reproductive age group.  An estimated 280 000 pregnant women are living with 
HIV in South Africa [2] with an estimated national HIV antenatal prevalence of 29.5% 
(95% CI: 28.7–30.2) in 2011 [3]. The estimated antenatal HIV prevalence in KwaZulu-
Natal (KZN) and some of its districts is higher than the national prevalence [3].  
Effective antenatal antiretroviral interventions aimed at preventing mother-to-child 
transmission (PMTCT) of HIV have been implemented worldwide as more than 90% of 
childhood HIV infections are due to vertical transmission of the virus during 
pregnancy, labour and delivery or breastfeeding.  Provision of antiretroviral 
interventions in low and middle income countries has prevented an estimated 850 000 
children from acquiring HIV infection between 2005 and 2012 [2]. In SSA, the 
implementation of effective antiretroviral treatment during pregnancy and breastfeeding 
has positively impacted on mother-to-child transmission (MTCT) of HIV [4-9]. 
Antiretroviral coverage for PMTCT in this region in 2012 however only expanded to 
83% (range 75%-90%) with a resultant MTCT of 7%. South Africa is categorized as a 
country that has made moderate progress with PMTCT coverage estimated at 83% [1].  
In South Africa, since 2008, the offer of an HIV test to all pregnant women is standard 
at initiation of antenatal care. First time attendees receive group counselling on the 
benefits and possible outcomes of an HIV test and individual rapid testing and 
disclosure of the result is performed by the clinic nurses or counsellors. In addition to 
HIV testing, a clinical history and examination is performed by the attending clinician 
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or nurse. CD4 assays are required in women diagnosed as living with HIV at this first 
visit.  
The recent South African PMTCT guidelines recommend the initiation of antiretroviral 
treatment (ART) in all pregnant women living with HIV irrespective of CD4 count 
[10]. Fixed dose combination (FDC) drugs have been made available and are to be 
initiated on site on the day of HIV diagnosis.  In women who initially test HIV 
uninfected, a repeat HIV test 12 weeks after the initial test and/or between 32 and 36 
weeks of gestation is advised. Additionally, at the time of HIV diagnosis, TB screening 
as well as isoniazid prophylaxis is advised in all pregnant women living with HIV [10].  
Although significant progress has occurred in the implementation of PMTCT 
programmes a number of health system factors and patient factors have impeded the 
success of the programme.  Time to initiation of ART, testing pregnant women for HIV 
and detection of acute seroconversion during pregnancy are some of the health service 
factors identified [11,12]. Screening for and treatment of opportunistic infections 
associated with HIV infection, particularly tuberculosis (TB), are additional challenges 
faced by health care workers in the management of a pregnant woman. Addressing 
these challenges is critical as acute seroconversion is associated with an increased 
vertical transmission rate and untreated OIs, particularly TB, impact on maternal and 
neonatal outcomes [13-17].  
Assessment of these factors within the South African PMTCT programme is necessary.  
Information is available, from routine collection of surveillance data, on the uptake of 
antenatal counselling and testing services for HIV in KZN. However, limited 
information is available in three key areas: firstly, time to initiation of ART following 
diagnosis of HIV; secondly, implementation of TB screening processes in pregnant 
women living with HIV; and thirdly, follow-up (HIV) testing in uninfected pregnant 
32 
 
women. The aim of this study was to explore the implementation of guidelines for the 
management of both seropositive and seronegative pregnant women in antenatal clinics 
in the metropolitan district with a focus on the following objectives: determining the 
median gestational age at diagnosis of HIV infection and at initiation of ART, 
ascertaining the distribution of CD4 counts among women living with HIV and 
assessing the application of TB screening process. In those women who were HIV 
uninfected, the study aimed to determine median the gestational age at initial and repeat 




An exploratory, observational, cross sectional study design presenting both descriptive 
and analytic statistics was implemented. Data was collected for a period of one year for 
women attending antenatal clinics between June 2013 and June 2014.  
Study setting and location 
The study was conducted in antenatal clinics within the Metropolitan district of 
eThekwini, in the KwaZulu-Natal Province of South Africa. 
Study population 
Patient records of women over the age of 18 years, presenting for follow-up care 
between 32 and 36 weeks of gestation and unaware of their HIV status at initiation of 
antenatal care were reviewed. Records of women, who presented for their first antenatal 
visit after 32 weeks, who had delivered prior to 32-36 weeks gestation or experienced 
pre-term labour, or in whom the HIV status was known prior to the current pregnancy, 





Data sets from antenatal clinics within the Metropolitan District were obtained from the 
District Health Information System. A total of 154 clinics offered antenatal care.  
Clinics with an average of less than 10 first time antenatal clients per month were 
excluded from the sampling frame (n=54). In addition clinics in which attendance totals 
did not tally, were also excluded (n=5). A total of 95 clinics from all administrative 
authorities were therefore eligible for inclusion in the study.  
A two stage cluster sampling, using a 30X7 strategy, was applied in the study; the first 
stage was implemented for the selection of clinics from the 95 eligible clinics; the 
second stage was to sample the records of pregnant women attending antenatal care 
within the clinics. Clinics were stratified into three categories depending on the average 
monthly number of first time antenatal attendees. Fifty four clinics had less than 50 
attendees, 28 clinics had between 50-99 attendees and 12 clinics had a 100 or more 
attendees. A total of 30 clinics were sampled with probability proportional to size to 
achieve representativeness. Seventeen clinics from the first stratum, nine from the 
second and four from the third stratum were selected. 
With regards to the records of pregnant women, we assumed that pregnant women 
present in random order to clinics and that consecutive, systematic sampling of clinic 
attendees would generate a representative sample of pregnant women. Seven HIV 
infected and seven uninfected women (based on the 30X7 sampling frame) were 
selected from the registers of each clinic.  
Data collection 
Data was collected from registers utilized in the antenatal servicesin the clinics. Data 
was extracted from the antenatal register, daily consultation registers, and antiretroviral 
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registers maintained by the nursing staff. For triangulation purposes, HIV counseling 
and testing logs were also reviewed to complete and verify data collected. 
All routinely collected data was collated and entered by the principal investigator onto 
the data collection sheet. Confidentiality was maintained by recording only patient 
initials and the clinic identifier. 
Variables of interest comprised both outcome and exposure variables. Exposure 
variables included age, parity, gestational age at first presentation to antenatal care, 
gestational age at initial HIV test, result of initial and rapid HIV rapid testing, CD4 
assay results and outcome of TB symptom checklist. Outcome variables comprised 
gestational age at which CD4 assay performed, administration of TB symptom 
checklist in women living with HIV and whether ART initiation occurred at the clinic 
level or referral occurred and whether ART was initiated by a nurse or doctor.  
Selected clinics were visited by the principal investigator for data collection. The 
antenatal register and daily consultation logs were reviewed first followed by a review 
of the supporting registers outlined above. Incomplete data sets were excluded from the 
data collection process and the replacement record was the next consecutive record. 
 
Data analysis and ethical approval 
All data for variables of interest were entered onto a Microsoft Excel spread sheet and 
imported into SPSS (IBM SPSS statistics version 21).  
Summary statistics are presented for demographic characteristics, initiation of FDC, TB 
screening processes and repeat testing in women who tested HIV uninfected. Statistical 
analysis was performed on exposure variables in relation to HIV status and the offer of 
a repeat test, the association between the administrative authority and practices within 
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and across clinics. Chi squared tests, Mann Whitney tests and t-tests were used to 
compare maternal characteristics. 
Ethical approval was obtained from the University of KwaZulu-Natal Biomedical 
Research Ethics Committee (reference number BE096/11). Permission to conduct the 




Data was collected from records of four hundred and twenty women, 210 living with 
HIV and 210 uninfected at the initial antenatal visit.  
Demographic profile 
Data extracted on the demographic profile is summarised in Table 1. Records showed 
that 94% of the women were from the black population. The mean age recorded was 25 
years (range 19-43 years, SD 5.3) and the mean gravidity recorded was 2.1 (range 1-7, 
SD 1.1).  
Booking at antenatal clinic 
Data extracted on the initiation of antenatal care showed that the majority of women 
(67.4%) presented for their first visit in the second trimester, with a median gestational 
age of 20 weeks (range 3-31, IQR 9). One hundred and nine women (51.9%) living 
with HIV and 93 HIV uninfected women (44.3%) presented before 20 weeks gestation.  
Initiation of FDC  
With regard to the initiation of FDC, records show that initiation at the first antenatal 
visit occurred in 203 women (96.7%) at a median gestational age of 19 weeks (range 5-
31, IQR 8). Twenty seven (13%) of these women living with HIV were recorded as 
having booked in the third trimester at a median gestational age of 28 weeks (range 27-
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31, IQR 5.8). Delayed initiation was observed in women who were recorded as not 
initiated on FDC in the antenatal clinic but referred to the facility based ART clinic for 
ART initiation. Of the women who were referred for ART access, records showed that 
one participant presented in the first trimester, five in the second and one in the third 
trimester.  There was lack of documentation in the records of these six women 
regarding initiation of FDC following referral. 
Distribution of CD4 counts in women living with HIV  
Of the 210 HIV infected women included in this study, 182 (87%) baseline CD4 counts 
were available for review. For 28 women, records of 28 CD4 results were not 
accessible; in 26 records the CD4 results were not documented, one record did not have 
any evidence that a sample was taken and in one record, there was no documentation 
that a repeat test was carried out after the initial sample was reported to have clotted. 
The median CD4 count was 399 cells/mm3 (range 1- 1158, IQR 229) with 57.7% of 
results concentrated between 200 to 500 cells/mm3. Figure one shows the baseline 
frequency distribution of CD4 counts. 
Tuberculosis screening practices 
Administration of the TB symptom questionnaire at the initial antenatal visit was 
documented in 191 (91%) of the 210 seropositive antenatal attendees. Six women were 
recorded as symptomatic and investigated by sputum sample collection. The CD4 
counts in these symptomatic women ranged between 145-812 cells/mm3. Records of 
TB screening (inclusive of the TB symptom questionnaire and sputum examination) 
were captured from a further 75 attendees.   
Adherence to TB guidelines 
Adherence to the guidelines did not appear to be consistent. The records of pregnant 
women from 24 clinics (80%) showed that TB symptom screening for women living 
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with HIV was implemented as advised by the guidelines. The records of pregnant 
women in five clinics did not have clearly detectable practices and in one clinic none of 
the records of pregnant women had any evidence of TB screening having been 
implemented. Isoniazid prophylaxis was documented in the records of 58 (30%) of the 
191 attendees screened. For one woman, initiation of isoniazid was recorded as 
occurring prior to FDC initiation, in 27 (46.6%) as occurring on the same day as FDC 
initiation, in 12 (20.7%) within two weeks, in 13 (22.4%) as being initiated a month 
later and in the remaining 5 (8.6%), as initiation occurring more than a month (range 2-
4) after initial antenatal contact.  
Repeat HIV rapid testing in women who test uninfected at first antenatal visit  
The records of pregnant women found to be HIV uninfected at initiation of antenatal 
care showed that retesting was recorded for 185 (88.1%) women. One hundred and 
seventy seven women were recorded as remaining HIV uninfected and eight (4.5%) 
were recorded as having seroconverted. The median gestational age at which repeat 
testing occurred was found to be 32 weeks (range 32-36, IQR 2). Records showed that 
84 women (45%) presented for antenatal care at or before 19 weeks and would have 
qualified for a repeat HIV test within 12 weeks of the initial test (at or before 31 weeks 
gestation). However, none of the women however were recorded as having been tested 
within 12 weeks but rather between 32 and 36 weeks gestation. The median delay in the 
offer of a repeat test was 9 weeks (range 0-19, IQR 6).  
The eight women who were recorded as having seroconverted attended six of the 30 
clinics sampled. The mean age of the seroconverters was noted to be 25 years (range 
21-34, SD 4.6). Three of the eight were recorded as primigravidas and were 
documented as the youngest of the eight. Presentation for the baseline antenatal visit in 
this subgroup was logged at a median gestational age of 14 weeks (range 9-21, IQR 
38 
 
7.5). Five of the eight women qualified for a repeat test within 12 weeks of initial 
booking according to documentation. However the repeat rapid HIV test was performed 
between 32 and 36 weeks with a median delay of 9 weeks (range 2-13, IQR 7). Records 
indicate that all women were initiated on FDC on the day that HIV infection was 
diagnosed.  
Women, for whom no repeat HIV rapid test results were recorded, can be categorized 
into two groups. One category in which documentation of deferment of these tests was 
captured and the other category for which no records were available in any of the 
registers reviewed. Testing was recorded as being deferred until the post delivery 
period in twelve women (48%). This deferment practice appeared to be clustered in five 
clinics with nine of the twelve women in whom testing was recorded as being deferred 
post delivery attending two clinics. For the thirteen women (52%) for whom no records 
were available, it can be assumed that repeat testing was not performed and these 
women were clustered in three of the sampled clinics. Both categories of women 
described above have documented regular antenatal visits following initiation of 
antenatal care, including visits during the recommended 32-36 week period for repeat 
testing. 
A summary of the movement of a typical seropositive and seronegative woman through 
the clinic processes is illustrated in figures one and two. Barriers identified within the 
clinic are highlighted in these figures. 
Statistical analysis 
Descriptive data illustrated certain trends which were subjected to analytic statistics to 
measure and associations were measured. An association was detected between HIV 
status and the median gestational age (Mann Whitney 0.076) at first antenatal visit. A 
statistically significant association was detected between HIV status and age (x2 18.739, 
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P<0.001) as well as HIV status and parity (x2 26.857, P=0.000). In women living with 
HIV, a higher immunological status as measured by the CD4 count was not associated 
with earlier health seeking behavior (x2 0.297, P<0.862).  
Recorded age of the women, gestational age at first antenatal visit, parity and the 
administrative authority of the clinic were not associated with the offer of a repeat HIV 
test. The association between the administrative authority and the implementation of 
TB screening practices (x2 7.949, P=0.019) and availability of CD4 counts (x2 7.183, 
P=0.007) was statistically significant. However no association was established between 




There were gaps observed and inconsistencies noted in record keeping. Of primary 
concern was the lack of data on baseline CD4 counts and results for the repeat HIV 
testing in women who initially tested uninfected. Upon review of missing records per 
clinic, four clinics did not record either of variables. Based on the data extracted from 
the department of health database, one of these clinics averaged more than 100 first 
time antenatal attendees and the other three averaged less than 50.  
Discussion  
 
This study describes the implementation of PMTCT guidelines for the management of 
HIV in pregnancy in antenatal clinics within the metropolitan district of eThekwini, in 
the KwaZulu-Natal Province of South Africa.  
Demographic profile: 
In this study women recorded as being HIV infected were mostly young between and 
including the ages of 19 and 33 years, and predominantly seeking antenatal care early 
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in the second trimester. The mean age of women living with HIV reflects the 
distribution of HIV infection in the general population, concentrated in the reproductive 
age group both in South Africa [3] and the international arena [1]. A statistically 
significant difference in recorded mean age of women infected and uninfected was 
detected in this study highlighting the continued vulnerability of young women to the 
HIV epidemic.  
A comparable median gestational age at first antenatal contact was recorded for both 
seropositive and seronegative women is reported probably reflecting similar health 
seeking practices. Equivalent mean gestational ages at first antenatal visit of 22 [18] 
and 19.2 weeks [19] have been documented in other South African studies. In the 
current study close to 20% of women presented in the first trimester, which provides 
significant opportunity to introduce two key interventions encapsulated in a successful 
PMTCT programme: the early initiation of FDC to improve maternal health and reduce 
vertical transmission to the neonate; and  individualized repeat HIV testing within 12 
weeks in women who test HIV uninfected at the initiation of antenatal care. The records 
of a majority of HIV infected women showed FDC initiation concurrent with HIV 
diagnosis, where HIV care was integrated with antenatal care. However, a delay in 
initiation of FDC was evidenced in the records of women referred to an on site 
antiretroviral clinic separate from antenatal care, emphasizing the deleterious effects of 
fragmented care [48,79]. Repeat HIV testing in women who tested HIV uninfected at 
initiation of antenatal care was recorded in 88% of women. However, rather than 
inidvidualised repeat testing within 12 weeks of the first antenatal visit, the offer of a 
repeat test was recorded as occurring routinely at a median gestational age of 32 weeks.  
Fragmentation of care and incorrect implementation of care guidelines contribute to a  
missed opportunity for optimal protection against vertical transmission offered both by 
41 
 
ART initiation and adequate duration of therapy. Lowered or suppressed maternal viral 
load is a benefit of a longer duration on ART thereby reducing the rate of vertical 
transmission [20]. Women in our study commenced FDC at an earlier median 
gestational age; however we are unable to comment on vertical transmission rates. The 
median gestational age at initiation of ART in the United Kingdom and Ireland was 
25.9 weeks (IQR 22.4–28.9 weeks) with an adjusted odds ratio of 0.90 per week of 
ART (p=0.007). Multivariate analysis showed that the lack of an (ART) intervention 
was the strongest risk factor for vertical transmission [20]. Evidence from a study in the 
Johannesburg area showed a marked difference in transmission rates between women 
on ART prior to pregnancy (0.7%) as compared to women initiated during pregnancy 
(5.7%) [5]. 
Inconsistent Tuberculosis screening practices 
Tuberculosis screening practices did not appear to be applied consistently across or 
within clinics and was dependent on administrative authority and a statistically 
significant difference between different administrative authorities and TB screening 
practices was detected. One third of the infected women who were screened, were 
initiated on INH at various time points after initial ANC contact. A possible reason for 
this is the lack of clarity in the national TB guidelines with regards to isoniazid 
initiation in relation to ART [21]. 
The World Health Organisation [22] and the South African National TB guidelines [21] 
recommend TB screening for those living with HIV and in individuals at high risk 
which includes pregnant women.  
Active TB disease has been detected in the pregnant population with the use of the TB 
symptom questionnaire and a variety of screening tests [23,24] underlining the 
importance of this antenatal opportunity.  Routine screening however is not standard of 
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care in many facilities. Training of nurses to administer the TB symptom questionnaire 
within antenatal services was required to improve coverage of TB screening [23,24]. 
Symptomatic pregnant women should be investigated as per country guideline and 
commenced on anti TB drugs if indicated. Untreated TB, advanced disease or delayed 
initiation of treatment is associated with adverse maternal and neonatal outcomes.  
Prematurity, small for gestational age newborns, low birth weight and perinatal death 
are associated with maternal TB [25,26]. The consequences of TB HIV co-infection in 
pregnancy include pre term labour, maternal mortality [14], fetal growth restriction, 
congenital TB, neonatal mortality [15], and an acceleration of the HIV replicative and 
disease processes. Tuberculosis is also recognised as an independent risk factor for the 
vertical transmission of HIV [27,28]. The importance of detection and immediate 
treatment of antenatal TB is therefore essential to improve maternal and neonatal 
outcomes.  
The South African TB guidelines recommend the use of INH despite the lack of 
evidence regarding its benefit in reducing active disease, the duration of prophylaxis 
and whether a second drug should be used [21]. Additionally there is a lack of data on 
the tolerance, safety, side effects and levels of adherence to INH in the pregnant 
population. The prescription of INH is further influenced by health care worker 
concerns regarding resistance, the ability to exclude active disease, the controversy 
surrounding the choice of screening tests [29,30,31] and unfamiliarity with national 
guidelines [32,33]. Training of health care workers on the evidence that is available on 
INH use and on the national guidelines could improve uptake of INH use in pregnancy.  
Retesting of women who initially test uninfected 
Women who tested uninfected at their first antenatal visit also accessed care early in the 
second trimester and were younger than those living with HIV. Retesting records were 
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available for 185 (88.1%) women and lack of documentation and deferment of tests 
occurred in 25 women (13.5%).  
The lack of re testing records, deferment of re testing and retesting only in the third 
trimester are matters of concern. Perhaps the confusion in retesting lies within the 
wording of the national PMTCT guidelines where it is recommended that seronegative 
women be retested within 12 weeks of the initial test and/or between 32 to 36 weeks of 
gestation. Not only does it highlight the need for reinforcement of PMTCT guidelines 
and the risk of vertical transmission but it also represents missed opportunities for re 
testing, the introduction of an appropriate PMTCT intervention and a possible under 
estimation of other seroconversions. A Tanzanian study also observed lack of records 
for HIV repeat testing in pregnancy despite national guidelines advocating retesting 
three months after the initial HIV test [34]. A lack of understanding of the window 
period was identified as the barrier to the offer of a repeat HIV test and retraining of 
HCWs was recommended [34]. 
A significant risk of incident HIV in pregnancy [18,35,36] as compared to non 
pregnancy [18,36] has been reported in studies in SSA. The incident rate per 100 
person years during pregnancy ranged from 2.3 cases [35] to 10.7 cases [18]. Some 
reports on the other hand show no increase in HIV risk during pregnancy [37,38].  
In this study, the proportion of HIV uninfected women who acutely seroconverted was 
4.5%. All eight women were between 21 and 34 years of age underlining the continued 
HIV transmission in this age group. Subsequent antenatal visits in women who initially 
test HIV uninfected should be capitalized upon to highlight the importance of safe 





Implementation of Guidelines 
It appeared that there were inter and intra clinic differences in the application of the 
national PMTCT and TB guidelines. Possible reasons for this could be the patient 
workload, the number of tasks performed by the health care worker, lack of support, 
mentorship, and regular feedback to staff, frequent staff turnover with no training of 
new staff, increased demand on services with the change in the national antiretroviral 
guidelines and increased consultation time. 
 Efforts to improve the SA PMTCT programme  
The revision of the national PMTCT guidelines [10], the integration of HIV services 
into maternal health services [39] and the implementation of NIMART [40] are efforts 
to improve PMTCT coverage in South Africa.  
Integration of services 
Successful integration of HIV services into maternal health services is demonstrated in 
this study. At the first antenatal visit, all women accessed an HIV test and the majority 
of women living with HIV initiated FDC. Lack of information on CD4 counts and FDC 
initiation in women referred to ART clinics for FDC however shows poor continuity of 
care and loss of information important to the overall management of the pregnant 
woman. This study was not designed to address the impact of integration of services on 
the number of women tested for HIV, time to initiation on ART or retention within care 
following ART. Other studies in SSA have shown a reduced time to initiation of ART 
in pregnancy with a 60% improvement in retention in care [41].  In South Africa [42] a 
median reduction of 19 days (P = 0.041) for time to initiation of ART was calculated 
and in Zambia, the odds of enrollment into HIV care (AOR 2.06) and initiation of ART 
(AOR 2.01) was higher in integrated facilities as compared to independent facilities 
[43]. Further rigorous research is required in these areas. 
45 
 
Poor integration of TB services into maternal health services was illustrated in this 
study as the administration of the TB symptom questionnaire, the investigation of all 
women living with HIV for TB and the offer of INH did not appear to be consistently 
administered across all facilities. Further the lack of feedback following referral of 
symptomatic women to the facility based TB unit for investigation suggests a 
fragmented rather than integrated approach.   
Nurse initiated management of ART  
Nurse initiated management of ART (NIMART) is a task shifting strategy adopted to 
address the scale up required of public sector ART provision [40]. Nurses are enabled 
to initiate and manage stable patients on ART. Access to ART has been ‘accelerated’ 
with the advent of NIMART. However, little has been written about the contribution of 
nurses to the antenatal sector in this regard. The immediate prescription of FDC by 
nurses in this study for women who were initially seropositive, who presented at an 
advanced gestational age and who seroconverted was facilitated by this training. These 
results were similar to another South African study which demonstrated the benefit of 
NIMART to women who presented in the third trimester and who would have been 
unable to access HIV care during pregnancy prior to NIMART [44]. 
Another South African study however described a delay in ART initiation following the 
introduction of NIMART in four of the five facilities reviewed [19]. Suggested 
contributory factors to this delay included possible staff shortages and the dedication of 
certain clinic days to NIMART in the early stages of the programme.  
Initiation of Antiretroviral treatment in pregnancy 
South Africa currently promotes Option B [38]. The CD4 count threshold for lifelong 
ART for the mother is 350 cells/mm3 and below with the duration of ART prophylaxis 
in women who have CD4 counts above this threshold directed by infant feeding choice 
46 
 
[38]. The CD4 result is no longer a requirement for the initiation of ART and the lack 
of CD4 results in women enrolled onto this study did not impact on their immediate 
access to ART. Access to and availability of CD4 results were often an obstacle to ART 
initiation in low income countries particularly when CD4 thresholds were used to 
determine ART eligibility. In a cross sectional retrospective evaluation at a large 
tertiary centre in KZN, a CD4 assay was not performed in 2.9% of women and an 
additional 31.3% did not receive their CD4 results [45]. As the CD4 count was used as 
a determining factor for ART eligibility at the time of the study, this lack of 
information prevented access to ART. Further 71.9% of women who qualified for ART 
according to their CD4 counts, did not access ART during pregnancy which resulted in 
a threefold higher in utero transmission of HIV to their neonates [45].  
 
Implications of our study 
This exploratory, observational cross sectional study forms the basis for future research 
on health system factors affecting care offered to pregnant women specifically in 
relation to ART initiation, TB screening practices and offer of repeat HIV tests. 
Training of staff on data collection principles and the national guidelines is crucial on 
two levels, one in relation to robustness of data and secondly and more importantly, the 
appropriate management of patients according to guidelines. 
Challenges and Limitations: 
Although due diligence was maintained in ensuring the integrity of this study, the 
following were the challenges and limitations of the study: 
Information bias: Data was extracted primarily from the antenatal register which is 
maintained by HCWs.  These registers were poorly completed and data fields were 
completed differently at both the first and follow up visits in the majority of clinics. A 
47 
 
number of other registers were maintained by different clinics and were consulted to 
ensure completeness of data. Sharing of the antenatal register amongst various 
categories of HCWs, staff shortages, lack of a unique patient identifier to link daily 
registers to entries in the antenatal register and lack of dedicated time to update the 
register are all possible contributors to the incomplete register. 
 
Conclusion and Recommendations: 
The focus of all PMTCT interventions is the prevention of transmission to the neonate 
and this is achieved by a lowered viral load resulting from a longer duration on ART. In 
this study, women presented at an early gestation allowing for timeous PMTCT 
interventions as required. The benefit of NIMART is evident in the immediate linkage 
of the majority of women living with HIV to ART. The deferment and the delays in the 
offer of a repeat test in women who initially test HIV uninfected are particularly 
concerning as is the loss to follow up of women referred for TB investigation and the 
delayed access to FDC.  
The following recommendations are proposed based on the findings of the study: 
Improving patient record keeping to ensure continuity of care - Careful attention to the 
completion of records for all patients accessing maternal health services is critical to the 
overall management and continuity of care of a pregnant female.  
Capacitation of health workers on correct application of national PMTCT and TB 
guidelines.  
Focus on HIV counseling and testing- attention to information provided to women who 




Improving data for action- Training specifically on data fields and the importance of 
complete data sets should be highlighted.  
Ongoing mentoring and supervision of Health Care Workers, particularly those 
involved in antenatal care. 
Further research using a more rigorous study design is required to investigate the gaps 
highlighted in this study. 
At a national or provincial level an audit of registers should be conducted and adaption 
of registers for ease of use by the health care worker, to capture salient information 
with the least amount of duplication should be considered.  
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Table 1: Demographic profile of antenatal attendees in 30 clinics within the 
metropolitan district  
 
Variable  HIV infected  HIV uninfected 
 Number (%)* Number (%)* 
Age in years in: 











































Median baseline gestational age (in 
weeks) 
 
19 (range 5.0-31.0,  
IQR 8.3) 
 
20 (range 3.0- 30.0,  
IQR 8) 
Median gestational age (in weeks) 
at repeat HIV rapid test 
 
32 (range 32-36, 
IQR 2) 
 











Median baseline CD4 count (cells/ 
mm3) 
 
399 (range 1-1158,  
IQR 229)  
 
Number initiated on fixed drug 
combination on first visit 






Nurse initiated FDC 203 (96.7) 
 
 
Mean number of days on ART at 
enrollment onto study 
 








*Percentages calculated after missing data was excluded 














Figure One: Frequency distribution of baseline CD4 counts in seropositive women  
 
Figure one shows the frequency distribution of CD4 counts at first antenatal visit in women 
who were diagnosed with HIV. This objective was included in the previous protocol as it was a 
determinant of initiation of ART with the CD4 threshold being above or below 350 cells/ 
mm3. With the introduction of the new PMTCT guidelines however, all women living with HIV 
are initiated on FDC upon diagnosis. The data presented in the figure serves to demonstrate 





Figure two: Flow of a typical patient through antenatal processes following a 















































Figure three: Flow of a typical patient through antenatal processes following a 








Chapter Four: Integrative Chapter 
 
Discussion 
This study aimed to assess the implementation of national PMTCT guidelines in 
seropositive and seronegative pregnant women attending antenatal clinics within the 
eThekwini metropolitan district between 2013 and 2014. The objectives of the study 
encompass the diagnosis and management of women tested for HIV in the antenatal 
period.  
Implementation of guidelines in women who test seropositive at initiation of antenatal 
care: 
The age group of women who were recorded as seropositive is reflective of the global 
HIV epidemiology and highlights the highest prevalence within the 18- 33 age group. 
With regard to initiation of antenatal care, the records showed that 18% of women 
booked prior to 14 weeks gestation and 48% presented early in the second trimester. 
The recorded ANC initiation is comparable to other South African studies where 
women presented at a median gestational age of 22 weeks [77] and 19.2 weeks [71]. 
The shift towards earlier antenatal attendance provides HCWs the opportunity to 
introduce an antiretroviral intervention in women who test seropositive at the initial 
antenatal visit. It also permits HCWs to increase awareness and re inforce HIV 
prevention strategies in women who test seronegative at the initial antenatal visit. 
 
With regard to ART initiation, the records showed that 97% of women were initiated 
at first antenatal visit upon diagnosis of HIV infection as per national PMTCT 
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guidelines. Referral of seven women (3.3%) for the initiation of ART was documented. 
Further, the unavailability of CD4 results in 28 (12.8%) women did not appear to 
impede access to ART. The National Guidelines recommend that all seropositive 
pregnant women be initiated on ART prior to the availability of CD4 results partly to 
reduce the system challenges associated with accessibility and availability of CD4 
assays. These challenges impeded access to ART when CD4 results were used to 
determine ART eligibility [32,66,80,81].  A three-fold higher in utero transmission of 
HIV was associated with delayed access to ART [83]. 
This study was not designed to assess the impact of the change in PMTCT guidelines 
on time to initiation of ART in the antenatal period and the duration on ART prior to 
delivery. Studies have shown differing outcomes in relation to this, from a reduction in 
median time to initiation of ART [69] to a lack of improvement in the duration on ART 
prior to delivery [68]. The overall number of women initiated on treatment however, 
did improve due to the integration of services [69,70]. 
The distribution of CD4 counts in this study indicated approximately one tenth of 
women had CD4 counts below 200 cells/mm3 and CD4 counts in the majority of 
women (57.7%) were clustered above 200 cells/mm3 and below 500 cells/mm3. The 
adoption of Option B+ in South Africa could present a challenge for the retention of 
clinically stable women with high CD4 counts within a post natal treatment 
programme as evidenced in Malawi [61]. The improvement in maternal health, the 
benefit to future pregnancies and the reduced risk of transmission to partners should 
be highlighted as additional benefits of adherence to Option B+ in an effort to retain 
women within the treatment programme. 
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Tuberculosis is a worldwide public health concern and co infection with HIV is seen in 
13% of HIV [34]. The HIV epidemic has triggered a shift in TB disease to women in the 
reproductive age group [35]. The expanded package of PMTCT services therefore 
recommends screening for TB and INH prophylaxis [1]. The TB symptom questionnaire 
should ideally be administered on an ongoing basis to seropositive pregnant women 
during the antenatal period [1]. Isoniazid should be introduced following the exclusion 
of active TB disease. In this study the symptom questionnaire was recorded as being 
administered in 91% of women and INH was recorded as being initiated in one third of 
women at varied time points following initial antenatal contact. Lack of clarity in 
guidelines regarding INH prescription, lack of information of INH use in pregnancy, lack 
of an understanding of guidelines and HCW concerns regarding resistance are some of 
the possible factors in the poor implementation of TB screening practices [39-43]. 
Some of these factors may have contributed to the statistically significant difference in 
the recorded TB screening practices by administrative authority. 
Routine TB screening and INH use does not appear to be standard practice within 
health care facilities. Tuberculosis screening practices were assessed in a 24 country 
HIV/ AIDS programme; only 15 sites recorded incident TB cases. Five sites routinely 
administered INH following the exclusion of active disease by the application of the TB 
screening questionnaire [81]. Reports of routine screening for TB and INH prescription 
within the pregnant population are limited. An improvement in the administration of 
the TB symptom questionnaire however, was detected following training of HCWs on 




The implementation of the guidelines in HIV uninfected women at initiation of 
antenatal care: 
Over 80% of women, who were recorded as seronegative at first presentation, were 
recorded as receiving a repeat test and more than half had qualified for a repeat test 
within three months of initial presentation. Two areas of concern were identified 
within this study that reflects inadequate implementation of guidelines. The first 
concern is that the repeat test was effected at a standardized rather than an 
individualized time point and is an important training point highlighted later. Although 
more than half of the seronegative women were recorded as qualifying for a repeat 
test within three months, all of them received a repeat test between 32 and 36 weeks 
gestation. The second concern was records showing the lack of and the deferment of a 
repeat test in women who are accessing regular antenatal care. The practice of 
deferring a repeat test until the post delivery period was documented in two clinics 
and is an additional training point. This is a critical oversight in the continuum of care 
as it has far reaching consequences. This single intervention of a repeat HIV test has 
the ability to impact on three of the eight Millenium Development Goals, specifically 
the reduction in child mortality by reducing vertical transmission of HIV, improvement 
in maternal health by improving the linkage to ART and combatting HIV/ AIDS, malaria 
and other diseases.  
Acute seroconversion was documented in eight women who received a repeat HIV 
test. The age of these eight women ranged between 21 years and 34 years highlighting 
the sustained acquisition of HIV in young women. All eight women were recorded as 
presenting at median gestational age of 14 weeks and the records of five women 
showed that they qualified for, but did not receive, a repeat HIV test within three 
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months. Seroconversion was at least two fold higher among 25 to 29 year olds (3.8%) 
and 30 to 34 year olds (4.5%) in another South African study [77]. 
Integration of services: 
Current PMTCT guidelines encompass both the antenatal and postnatal periods in an 
effort to improve maternal and newborn health outcomes. The shift in approach 
towards the integration of HIV services within an established PMTCT network could 
result in strengthening and efficiency of the health system.  
Successful integration of HIV testing, linkage to ART and nurse initiation of ART within 
antenatal care was displayed in this study. Two areas of concern include the referral of 
women for ART initiation and the lack of CD4 results in records reviewed. 
Improvement in maternal HIV care following the integration of services has not always 
been demonstrated [69-71]. Partial integration of TB services into maternal health 
services is detailed above. Records of symptomatic women who were referred for 
further investigation did not reflect the  outcome of these investigations. Feedback 
mechanisms and communication between different services within a clinic clearly 
needs to be strengthened for both TB and HIV referrals and investigations as it 
impacts on overall management of the mother. 
 
Missed opportunities and the impact of these challenges: 
A missed opportunity refers to instances where patients come into contact with the 
health care system and an appropriate intervention does not occur. The missed 
opportunities in this study with the possible implications are outlined below. 
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1. The WHO guidelines [54] and the national PMTCT guidelines [1] recommend the 
introduction of ART upon diagnosis of HIV infection at first antenatal interaction. 
Referral for initiation of ART however was documented in this study in some 
clinics, with a resultant delay in linkage to ART and a decreased duration on ART 
prior to delivery. Difficulties in the linkage of pregnant women to an appropriate 
ART intervention were widespread prior to integration [82] and the risk of 
transmission to the fetus subsequently increased with delayed initiation [83].  
2. The delay in the offer of a repeat HIV test within 12 weeks of initial test (as per 
guidelines) in 45% of women was identified in this study. The basis for repeat 
testing is two-fold: firstly to detect acute seroconversion and initiate ART upon 
detection of seroconversion. Acute seroconversion is associated with an increased 
risk of MTCT and a PMTCT intervention should be offered timeously to reduce this 
risk. From a maternal health perspective, HIV has been identified as the 
commonest non pregnancy related cause of maternal deaths and the introduction 
of an appropriate ART regimen could impact on maternal mortality [14]. There 
appears to be a consistent misinterpretation of country specific guidelines [86] and 
the lack of individualised repeat testing may be poorly understood. This lack of 
understanding could be as a result of poor formulation of the guidelines or poor 
understanding of guidelines or a combination of both factors. 
3. Inconsistent TB screening practices were detected within and across sampled 
clinics. Of concern were the clinics which did not have clearly detectable practices 
and the clinic that did not adhere to the guidelines. Although the diagnosis of TB in 
pregnancy is problematic, a high index of suspicion should be maintained in areas 
with a high TB burden. Maternal and perinatal deaths, low birth weight and small 
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for gestational age newborns are a consequence of untreated TB or delayed TB 
treatment [16-18].  
 
Recommendations: 
It is evident that training and support of health care workers on multiple levels is 
essential. The following were identified as areas requiring training and support.  
1. Limited understanding of the PMTCT guidelines: 
Strengthening and improving health worker understanding of the national PMTCT 
guidelines and the impact of precise implementation on maternal health and 
vertical transmission of HIV, particularly with regard to acute seroconversion, is 
fundamental. An additional intervention at improving implementation is for 
ongoing facility level monitoring, evaluation and feedback to occur following this 
training the intervention.  
2. Inconsistent TB screening practices: 
It appeared that there was a variation in the application of the guidelines within 
and between clinics. This variation could potentially be rectified by additional 
training of HCWs or mentorship of HCWs as evidenced by other studies [36,37,86]. 
The inconsistent INH initiation needs to be addressed at facility level in relation to 
understating of guidelines and at a national level to clarify its use.   
3. Inconsistent and incomplete data collection: 
The integration of services warrants additional attention be directed to the 
capturing of records. At first contact, prescribed data fields are captured in the 
antenatal register and subsequent consultations are captured on a daily basis in 
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facility specific tools. The completion of data fields in the antenatal register varies 
and reconciliation of data from subsequent visits is difficult as patient identifiers 
are log specific. Improvements in data completion and collection require training 
and mentoring at facility level on the importance of robust data sets . Regular 
review of registers should be conducted with feedback within facilities and 
adaptation of registers to capture salient information with the least amount of 
duplication is suggested at a national level. Other interventions include 
maintenance of a centrally located register in a facility that is shared and updated 
by various categories of HCWs with dedicated time to updating this register. Nurse 
quality mentors were trained to supervise HCWs in three provinces in SA and 
through this intervention, data quality improved [86]. 
4. It is recommended that health care providers capitilise on subsequent antenatal 
visits for women who initially test seronegative to improve awareness related to 
HIV prevention and acquisition. The risks of acute seroconversion, the importance 
of consistent condom use, partner involvement and counseling as well as the offer 
of ART in sero discordant couples should all be addressed. 
5. Suggested future research based on the exploratory analysis within this study: 
a. Multi centre, prospective cohort study in seropositive focusing on the 
following parameters: 
i. Time to initiation of ART prior to and following introduction of 
Option B  




iii. Impact of earlier initiation of ART on maternal and newborn 
outcomes within a South African context. 
b. Health systems research: 
i. Interventional studies following training of HCWs on national 
guidelines and on data capturing. 
c. Facility level monitoring and evaluation with feedback, assess the impact of  
Conclusion 
This exploratory, observational, cross sectional study demonstrated successful 
integration of HIV testing and initiation of ART into antenatal services. Implementation 
of HIV repeat testing within prescribed time frames however was identified as an area 
of concern. The implementation of TB screening practices and INH initiation was 
partially successful. Interventions to improve the delivery of TB and HIV services 
within the extended PMTCT programme are needed. This study forms the basis for 
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Background: The contribution of the HIV epidemic to morbidity and mortality in pregnancy has 
been well documented. Despite the overwhelming impact on maternal and child health globally, 
less than a quarter of women accessed counseling and testing for HIV in pregnancy and less than 
half accessed an intervention aimed at preventing mother-to-child transmission (PMTCT) 
following counseling and testing. Provider initiated HIV counseling and testing in a number of 
health care facilities including antenatal clinics, was recommended in an attempt to improve 
health outcomes within the expanding HIV epidemic. 
 
Purpose: The study aims to explore the implementation of care for pregnant women living with 
HIV, specifically initiation of antiretroviral therapy and the tuberculosis screening process.  
Further, the study aims to determine follow up HIV testing in women who are uninfected at their 
first antenatal visit.  
 
Objectives: The objectives for women living with HIV are to determine the gestational age at 
which women are diagnosed with HIV infection, describe the distribution of CD4 counts, 
determine the gestational age at which antiretroviral treatment is initiated and to determine the 
proportion of pregnant women living with HIV who are screened for tuberculosis at the visit at 
which HIV infection is diagnosed. The objectives in those women who are HIV uninfected are to 
determine the gestational age at which diagnosed uninfected, determine the gestational age at 
which a second HIV test is offered and to describe the proportion who seroconvert.  
 
Study design: An exploratory, observational, cross-sectional study design presenting both 
descriptive and analytic statistics will be used. 
Setting: The study will be conducted at a sample of clinics within the eThekwini Municipality 
offering antenatal care. Offering an HIV test to all pregnant women is standard of care at all 
antenatal clinics.  
Study population and study sample: The study population will be those women attending the 
ANC between 32-36 weeks gestation for the current pregnancy. The management of both women 
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living with HIV and those that are HIV uninfected, will be documented according to the 
objectives outlined above. 
Data collection: Information related to study variables will be captured on the data capture sheet 
by the investigator or a trained field worker (see attached data sheet). Data entered onto the data 
capture sheet from the patient charts will be compared to the PMTCT register for confirmation 
and to add any missing information. All data will be captured onto an SPSS worksheet for 
processing and analysis. 
Statistical methods: Descriptive statistics specifically the measures of central tendency will be 
used for all points of the care cascade. In addition for the analytic component of the study, a two 
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Appendix 1: List of abbreviations 
 
ANC   antenatal clinics  
ART   antiretroviral therapy 
AZT   zidovudine 
CD4   cluster of differentiation 4 
HIV   human immunodeficiency virus  
MTCT   mother-to-child transmission 
PMTCT   preventing mother-to-child transmission 
SPSS statistical package, originally used as a Statistical Package for the Social 
Sciences 
TB   tuberculosis 



















Title of study: 
Diagnosis and management of HIV infection in women attending antenatal clinics in the 
eThekwini Municipality in 2011. 
Aim of study 
The aim of this study is to establish the uptake and management of human immunodeficiency 
virus (HIV) counseling and testing in pregnant women attending antenatal clinics (ANC) within 
the eThekwini Municipality in 2011.  
Specific objectives:  
Data on HIV counselling in pregnancy will be collected. The study will include information on 
both HIV counselling and follow up management of two groups of women, women living with 
HIV and women diagnosed as HIV uninfected at their first antenatal clinic visit.  
The objectives for women who were found to be HIV infected at the initiation of ANC were to 
determine: 
a) the median gestational age at diagnosis of HIV infection; 
b) the distribution of CD4 counts; 
c) the median gestational age at initiation of which antiretroviral treatment (ART); and 
d) Screening practices for tuberculosis and opportunistic infections.   
The objectives for women who were found to be HIV uninfected at initiation of ANC were to 
determine: 
a) the median gestational age at initial and repeat HIV test; 
b) the proportion who seroconvert during pregnancy. 
Background and literature 
Women and girls account for over half of the estimated number of people living with HIV 
globally.1 The highest burden of disease is concentrated in women in the reproductive age group. 
The contribution of the HIV epidemic to morbidity and mortality in pregnancy has been well 
77 
 
documented.2,3 In South Africa, the Saving Mothers Report documents the outcomes of the 
confidential enquiry into maternal deaths and HIV was identified as the biggest single cause of 
maternal deaths, at 44% in the most recent report.4 More than 90% of childhood HIV infections 
are due to mother-to-child  transmission (MTCT). An estimated 2.5 million children (estimated 
range of 1.7 million-3.4 million) were living with HIV and 260 000 children died from AIDS-
related illnesses at the end of 2009.1    
 
Despite this overwhelming impact on maternal and child health globally, only 18 to 21% of 
women accessed counseling and testing for HIV in pregnancy and an average of 33 to 45% 
accessed an intervention aimed at preventing mother-to-child  transmission (PMTCT) thereafter.1 
Successful PMTCT programmes in high income countries have reduced the MTCT rate to 1%; 
however MTCT remain high in low income  countries at 15 to40%.1,5 Provider initiated HIV 
counseling and testing in a number of health care facilities was recommended in an attempt to 
improve health outcomes within this expanding HIV epidemic.6 
 
Antenatal clinics are often the first point of contact with health care for many females living with 
HIV. Testing for HIV infection at ANC facilitates access to HIV management in pregnancy 
which improves both maternal and neonatal outcomes.7 Provider initiated HIV testing in 
pregnancy is therefore identified as a key objective in the South African National HIV and AIDS 
and STI Strategic Plan.8 KwaZulu-Natal had the highest ANC HIV prevalence at 39% in 2009.9 
Information is available from routine surveillance data on the uptake of the antenatal counselling 
and testing services for HIV. However, limited information is available in three key areas: firstly, 
gestational age at initiation of the relevant antiretroviral therapy; secondly, implementation of TB 
screening processes in pregnant women living with HIV; and thirdly, follow up (HIV) testing in 
uninfected pregnant women.   
 
This study therefore aims to explore the implementation of care for pregnant women living with 
HIV, specifically initiation of antiretroviral therapy and the TB screening process.  Further, the 
study aims to determine follow up HIV testing in women who are uninfected at their first 





Preventing mother–to-child transmission (PMTCT) 10: There are four elements to the national 
PMTCT policy. These include primary prevention of HIV, especially among women of child-
bearing age; integration of PMTCT interventions with basic antenatal care, sexual and 
reproductive health, child and adolescent health and TB services; strengthening postnatal care for 
the mother-baby pair and provision of an expanded package of PMTCT services. The scope of 
this study allows capturing of information related to the second and fourth elements.  
Antiretroviral therapy is a combination of three antiretroviral drugs. National PMTCT 
antiretroviral guidelines currently recommend a fixed dose combination of lamivudine or 
emtracitabine, tenofovir and efavirenz, provided that there are no contra indications to any of the 
drugs. 10  
Study methods 
6.1 Study location 
The study will be conducted at clinics within the eThekwini Municipality offering antenatal 
care. A random sample of clinics will be selected for the purposes of this study.   
6.2 Study setting 
Offering an HIV test to all pregnant women is standard of care at all antenatal clinics. Women 
identified as first time attendees receive group counselling on the benefits and possible 
outcomes of an HIV test. Rapid HIV testing is then individually performed by the clinic 
nurses on women who consent to testing. The result of the test is then disclosed to the woman 
with the relevant advice. The attending clinician or senior nurse at the clinic will document 
the gestational age based on the date of the last normal menstrual period, perform a clinical 
examination and if required, an ultrasound investigation. In women living with HIV, WHO 




The current PMTCT guidelines advise that all pregnant women are initiated on ART 
irrespective of their CD4 count. Fixed dose combinations have been made available and are to 
be initiated on site on the day of HIV diagnosis. 
6.3 Study population 
The study population will be those women attending the ANC between 32 and 36 weeks 
gestation for the current pregnancy. The management of both women living with HIV and 
those that are HIV uninfected, will be documented according to the objectives outlined above. 
The target population for the study will then be attendees at antenatal clinics within the 
eThekwini Municipality.  
 Study design 
7.1 Type of research 
This study can be categorized as health systems research. 
7.2 Study design 
An exploratory, observational, cross-sectional study design presenting both descriptive and 
analytic statistics will be used. 
7.3 Study period 
The data for the retrospective review will be collected over a period of one year months 
between June 2013 and June 2014. Analysis and write up will occur over the following year. 
The total period for data collection and analysis will thus be 18 months.  
7.4 Inclusion and exclusion criteria 
The inclusion criteria for the study include: 
7.4.1. Pregnant women over the age of 18 years attending ANC in eThekwini district 
clinics; 
 7.4.2. Pregnant women between 32 and 36 week gestational age; and 
 7.4.3. Women who accept the offer for an HIV test. 
 The exclusion criteria include: 
 7.4.4. Women whose first ANC visit occurs after 32 weeks; 
7.4.5. Women who delivered prior to 32-36 weeks gestation/ pre term labour; and 
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 7.4.6. Women whose HIV status was known prior to the current pregnancy. 
7.5 Sampling strategy and sample size  
Two data sets from antenatal clinics within the eThekwini municipality were obtained 
from the Department of Health. The variable of interest for sampling of clinics in this 
protocol was the number of clients attending the facility for the following visits: 
 First antenatal visit, 
 First antenatal visit occurring at 20 weeks or later, 
 First antenatal visit occurring before 20 weeks, and 
 Follow up (antenatal) visits. 
Data for monthly antenatal attendance between and including January 2012 to December 
2012 was reviewed. Further data on the other three factors listed above was only available 
between and including January 2012 to September 2012.  
A total of 154 clinics within the eThekwini municipality offered antenatal care during this 
time frame. Clinics with an average of less than 10 clients per month were excluded from 
the sampling frame (n=54). In addition clinics in which attendance totals did not tally, 
were also excluded (n=5). A total of 95 clinics were therefore included in the sampling 
frame.  
A two stage cluster sampling of 30 X 7 strategy is being proposed for the selection of 
clinics from the eligible clinics. The clinics were stratified into three categories depending 
on the average monthly number of antenatal attendees presenting for first time antenatal 
visits. Fifty four clinics had less than 50 attendees, 28 clinics had between 50-99 attendees 
and 12 clinics had a 100 or more attendees. A total of 30 clinics were then proportionally 
sampled to achieve representativeness. Seventeen clinics from the first stratum, nine from 
the second and four from the third stratum were then selected for data collection. 
If we assume pregnant women present in random order to the clinics chosen, consecutive 
sampling of this population will generate a representative sample of the population in that 
area. For the descriptive purposes of this study, the sample will be constrained by the 
number of women between 32 to 36 weeks gestation that present to the chosen clinic on 
that day. All charts will be reviewed for eligibility and data will be captured as outlined. 
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Data on seven HIV infected and seven uninfected women (based on the 30X7 sampling 
frame) will be captured.  
Data collection methods and tools 
Women attending the ANC for the first time are issued an ANC card at that visit.  Relevant 
information is recorded in this card and includes:  
 Demographic data; 
 The date of the first offer of an HIV test;  
 The result of the (rapid) HIV test; 
 The date and result of the CD4 count; and 
 The initiation date of the antiretroviral therapy intervention. 
The clinic has a PMTCT register which also captures this information. 
Information related to study variables outlined in section 9 will be captured on the data 
capture sheet by the investigator or a trained field worker (see attached data sheet). Data 
entered onto the data capture sheet from the patient charts will be compared to the PMTCT 
register for confirmation and to add any missing information. 
Data from the data capture sheets will be entered onto an SPSS worksheet for processing and 
analysis. 
Statistical planning (variables) 
List of variables for collection: 
 Age 
 Parity 
 Gestational age at first ANC visit and number of subsequent antenatal visits 
 Gestational age at which HIV test done in current pregnancy 
 Result of HIV rapid tests 
 Gestational age at which CD4 count taken 
 Gestational age at which CD4 count results received 
 Results of CD4 assays 
 Gestational age at which (first) diagnosed uninfected 
 Gestational age at which a second HIV test offered and performed 
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 Result of second HIV test 
 TB symptom checklist administered in those women living with HIV 
 Outcome of TB symptom checklist 
 Initiation of antiretroviral therapy occurred at the clinic or referral to local hospital for 
antiretroviral therapy initiation 
 Antiretroviral therapy initiated by nurse or doctor 
Measures to improve validity: 
Multiple sources of data collection will be used to verify information collected. The patient file will be the 
primary source of data and the accuracy of this information will be checked against the clinic registers and 
the PMTCT registers. 
 Measures to reduce bias:  
Selection bias will be overcome by consecutive sampling of all eligible antenatal attendees. 
Information bias will be addressed by training of field workers on use of data collection form and 
understanding of the PMTCT register to extract data. 
Data quality, storage and safety  
Multiple sources of data will help improve data quality. 
Once data has been extracted all the data capture sheets will be completed and kept in a locked 
cupboard. Data will be shared among members of the research team and for the purposes of a 
report, otherwise data will be handled as confidential. 
Data analysis techniques 
The analytic component of the study will be derived from measuring the data collected against 
the standard of care outlined in National PMTCT Guidelines.  
Statistical analysis 
Data capturing and statistical analysis will be performed using SPSS version 18. Descriptive 
statistics specifically the measures of central tendency will be used for all points of the care 
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cascade. The mean gestational age, the median CD4 count and median time to antiretroviral 
therapy initiation, the proportion screened for TB and the proportion of HIV uninfected women 
who seroconvert with a seroconversion rate per unit time are some of the statistics that will be 
reported. In addition, a two-sided one sample t-test will be used to test for the analytic 
component; specifically the lag time to implementation of ART intervention as compared to the 
timelines outlined in the National PMTCT Guidelines.  
15.      Limitations of the study 
15.1 There may be missing data in the patient charts and PMTCT register. This is a limitation of 
using a retrospective chart review. However, by using multiple data sources, minimisation of 
missing data should result. Further laboratory results can be tracked by the investigator on the 
laboratory data management system if necessary.  
15.2 Antenatal clinics schedule repeat antenatal visits on a specific day of the week. Sampling 
would have to occur on these days and might introduce a bias since these attendees may not 
adhere to appointment days and the sample may then have women who are being managed 
differently.  
16.  Ethical considerations 
No additional harm will result from participation in this study. The routine antenatal data from 
each clinic will be collected and analysed. There will be no immediate benefit to the participants 
of the study; however, there may be an operational systems benefit for future ANC attendees 
depending on the results from the study.  
 
Ethical approval for this study will be sought from the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal. Further permission will be obtained from the national and 




17.  Budget:  
The budget will be related to travel costs incurred on travel to the clinics sampled, to the 
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Background: The contribution of the HIV epidemic to morbidity and mortality in pregnancy has 
been well documented. Despite the overwhelming impact on maternal and child health globally, 
less than a quarter of women accessed counseling and testing for HIV in pregnancy and less than 
half accessed an intervention aimed at preventing mother-to-child transmission (PMTCT) 
following counseling and testing. Provider initiated HIV counseling and testing in a number of 
health care facilities including antenatal clinics, was recommended in an attempt to improve 
health outcomes within the expanding HIV epidemic. 
 
Purpose: The study aims to explore the implementation of care for pregnant women living with 
HIV, specifically initiation of short course antiretroviral therapy for the purposes of PMTCT in 
women who do not meet eligibility criteria for antiretroviral therapy, initiation of antiretroviral 
therapy when indicated on clinical or immunological basis, and the tuberculosis screening 
process.  Further, the study aims to determine follow up HIV testing in women who are 
uninfected at their first antenatal visit.  
 
Objectives: The objectives for women living with HIV are to determine the median gestational 
age at which HIV infection is diagnosed, describe the distribution of CD4 counts, determine the 
median gestational age at initiation of antiretroviral treatment and to determine the TB screening 
practices. The objectives in those women who are HIV uninfected are to determine the median 
gestational age at initial and repeat HIV testing and to describe the proportion who seroconvert.  
 
Study design: An exploratory, observational, cross-sectional study design with descriptive and 
analytic statistics will be used. 
Setting: The study will be conducted at a sample of clinics within the eThekwini Municipality 
offering antenatal care. Offering an HIV test to all pregnant women is standard of care at all 
antenatal clinics.  
Study population and study sample: The study population will be review of records of those 
women attending the ANC between 32-36 weeks gestation for the current pregnancy. The 
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management of both women living with HIV and those that are HIV uninfected, will be 
documented according to the objectives outlined above. 
Data collection: Information related to study variables will be captured on the data capture sheet 
by the investigator or a trained field worker (see attached data sheet). Data entered onto the data 
capture sheet from the patient charts will be compared to the PMTCT register for confirmation 
and to add any missing information. All data will be captured onto an SPSS worksheet for 
processing and analysis. 
Statistical methods: Descriptive statistics specifically the measures of central tendency will be 
used for all points of the care cascade. In addition for the analytic component of the study, a two 
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Appendix 1: List of abbreviations 
 
ANC   antenatal clinics  
ART   antiretroviral therapy 
AZT   zidovudine 
CD4   cluster of differentiation 4 
HIV   human immunodeficiency virus  
MTCT   mother-to-child transmission 
PMTCT   preventing mother-to-child transmission 
SPSS statistical package, originally used as a Statistical Package for the Social 
Package 
TB   tuberculosis 






























1. Title of study: 
Diagnosis and management of HIV infection in women attending antenatal clinics in the 
eThekwini Municipality in 2011. 
2. Aim of study 
The aim of this study is to establish the uptake and management of human immunodeficiency 
virus (HIV) counseling and testing in pregnant women attending antenatal clinics (ANC) within 
the eThekwini Municipality in 2011.  
3. Specific objectives:  
Data on HIV counselling in pregnancy will be collected. The study will include information on 
both HIV counselling and follow up management of two groups of women, women living with 
HIV and women diagnosed as HIV uninfected at their first antenatal clinic visit.  
 
The objectives for women living with HIV are to: 
a) Determine the gestational age at which women are diagnosed with HIV infection; 
b) Describe the distribution of CD4 counts; 
c) Determine the gestational age at which the appropriate antiretroviral (ART) intervention is 
initiated; and 
d) Determine the proportion of pregnant women living with HIV who are screened for 
tuberculosis (TB) at the visit at which HIV infection is diagnosed.   
The objectives in HIV uninfected women are to: 
a) Determine the gestational age at which women are diagnosed uninfected; 
b) Determine the gestational age at which a second HIV test is offered to women; and  
c) Describe the seroconversion rate in pregnant women following an initial HIV negative test. 
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4. Background and literature 
Women and girls account for over half of the estimated number of people living with HIV 
globally.1 The highest burden of disease is concentrated in women in the reproductive age group. 
The contribution of the HIV epidemic to morbidity and mortality in pregnancy has been well 
documented.2,3 In South Africa, the Saving Mothers Report documents the outcomes of the 
confidential enquiry into maternal deaths and HIV was identified as the biggest single cause of 
maternal deaths, at 44% in the most recent report.4 More than 90% of childhood HIV infections 
are due to mother-to-child  transmission (MTCT). An estimated 2.5 million children (estimated 
range of 1.7 million-3.4 million) were living with HIV and 260 000 children died from AIDS-
related illnesses at the end of 2009.1    
 
Despite this overwhelming impact on maternal and child health globally, only 18 to 21% of 
women accessed counseling and testing for HIV in pregnancy and an average of 33 to 45% 
accessed an intervention aimed at preventing mother-to-child  transmission (PMTCT) thereafter.1 
Successful PMTCT programmes in high income countries have reduced the MTCT rate to 1%; 
however MTCT remain high in low income  countries at 15 to40%.1,5 Provider initiated HIV 
counseling and testing in a number of health care facilities was recommended in an attempt to 
improve health outcomes within this expanding HIV epidemic.6 
 
Antenatal clinics are often the first point of contact with health care for many females living with 
HIV. Testing for HIV infection at ANC facilitates access to HIV management in pregnancy 
which improves both maternal and neonatal outcomes.7 Provider initiated HIV testing in 
pregnancy is therefore identified as a key objective in the South African National HIV and AIDS 
and STI Strategic Plan.8 KwaZulu-Natal had the highest ANC HIV prevalence at 39% in 2009.9 
Information is available from routine surveillance data on the uptake of the antenatal counselling 
and testing services for HIV. However, limited information is available in three key areas: firstly, 
gestational age at initiation of the relevant antiretroviral therapy; secondly, implementation of TB 
screening processes in pregnant women living with HIV; and thirdly, follow up (HIV) testing in 




This study therefore aims to explore the implementation of care for pregnant women living with 
HIV, specifically initiation of short course antiretroviral therapy for the purposes of PMTCT in 
women who do not meet eligibility criteria for antiretroviral therapy, initiation of antiretroviral 
therapy when indicated on clinical or immunological basis, the TB screening process.  Further, 
the study aims to determine follow up HIV testing in women who are uninfected at their first 
antenatal visit.  
Definitions: 
Appropriate antiretroviral treatment: According to National PMTCT guidelines 10, a course 
of zidovudine (AZT) should be commenced from 14 weeks gestation onwards in women living 
with HIV with CD4 counts above 350 cells/ mm3. Ideally this should be commenced upon 
diagnosis of HIV infection and discontinued upon receipt of CD4 count results below 350 cells/ 
mm3. Women with CD4 counts below 350 cells/ mm3 irrespective of World Health Organisation 
(WHO) clinical staging for HIV qualify for initiation of antiretroviral therapy within two weeks 
(‘fast tracking’). 
 
Preventing mother–to-child transmission (PMTCT) 10: There are four elements to the 
national PMTCT policy. These include primary prevention of HIV, especially among women of 
child-bearing age; integration of PMTCT interventions with basic antenatal care, sexual and 
reproductive health, child and adolescent health and TB services; strengthening postnatal care for 
the mother-baby pair and provision of an expanded package of PMTCT services. The scope of 
this study allows capturing of information related to the second and fourth elements.  
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Antiretroviral therapy is a combination of three antiretroviral drugs. National PMTCT 
antiretroviral guidelines currently recommend a combination of lamivudine, tenofivir and 
nevaripine. 10  
5. Study methods 
5.1 Study location 
The study will be conducted at clinics within the eThekwini Municipality offering antenatal 
care. The referral system within the municipality links clinics within a certain geographic 
region to a dedicated district- level hospital. An average of 10 to 14 clinics are linked to a 
district- level hospital and for the purposes of this study, a single referral stream of clinics 
will be selected.  
5.2 Study setting 
Offering an HIV test to all pregnant women is standard of care at all antenatal clinics. Women 
identified as first time attendees receive group counselling on the benefits and possible 
outcomes of an HIV test. Rapid HIV testing is then individually performed by the clinic 
nurses on women who consent to testing. The result of the test is then disclosed to the woman 
with the relevant advice. The attending clinician or senior nurse at the clinic will document 
the gestational age based on the date of the last normal menstrual period, perform a clinical 
examination and if required, an ultrasound investigation. In women living with HIV, WHO 
clinical staging of disease and CD4 assays are recommended at this first visit.  
 
The follow up of women living with HIV involves a review of the CD4 count within the 
week in keeping with a one-week turn around time for CD4 count results. Additionally, those 
with WHO clinical stage 3 or 4, co-infected with TB or with CD4 counts below 350 cells/ 
mm3 require initiation of antiretroviral therapy within two weeks. In women who do not meet 
these criteria, prophylaxis with zidovudine is recommended from 14 weeks gestation.  
5.3 Study population 
The study population will be records of those women attending the ANC between 32 and36 
weeks gestation for the current pregnancy. The management of both women living with HIV 
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and those that are HIV uninfected, will be documented according to the objectives outlined 
above. The target population for the study will then be attendees at antenatal clinics within 
the eThekwini Municipality.  
6.  Study design 
6.1 Type of research 
This study can be categorized as health systems research. 
6.2 Study design 
An exploratory, observational, cross-sectional study design will be used. 
6.3 Study period 
 The data for the retrospective review will be collected over a period of six months between 
July 2011 and December 2011. Analysis and write up will occur over the following year. The 
total period for data collection and analysis will thus be 18 months.  
6.4 Inclusion and exclusion criteria 
The inclusion criteria for the study include: 
6.4.1. Pregnant women over the age of 18 years attending ANC in eThekwini district 
clinics; 
 6.4.2. Pregnant women between 32 and 36 week gestational age; and 
 6.4.3. Women who accept the offer for an HIV test. 
  
The exclusion criteria include: 
 
 6.4.4. Women whose first ANC visit occurs after 32 weeks; 
6.4.5. Women who delivered prior to 32-36 weeks gestation/ pre term labour; and 
 6.4.6. Women whose HIV status was known prior to the current pregnancy. 
6.5 Sampling strategy and sample size  
A multi stage sampling process will be used. Referral systems will be identified and a 
single referral system will be chosen at random. On average 10 to14 clinics refer to one 
district- level hospital. The number of attendees at these clinics is documented in the 
District Health Information System. All clinics within this one referral system will be 
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sampled for two groups of women: those living with HIV either requiring AZT 
prophylaxis or antiretroviral therapy and those uninfected at their first ANC visit.  
A specific clinic will be visited on one randomly chosen day of the week to review charts 
and documents for that day to identify all women between 32 and 36 weeks gestation who 
accepted an HIV test at their first ANC visit.  
If we assume pregnant women present in random order to the clinics chosen, consecutive 
sampling of this population will generate a representative sample of the population in that 
area. For the descriptive purposes of this study, the sample will be constrained by the 
number of women between 32 to 36 weeks gestation that present to the chosen clinic on 
that day. All charts will be reviewed for eligibility and data will be captured as outlined. 
Data on the maximum number of patients that can be obtained within a specific timeframe 
will be captured.  
For the analytic component, the sample size calculation was based on a provincial HIV 
prevalence of 39%. With the null hypothesis of time to ART initiation being 14 days and 
the alternate hypothesis being 20 days, a total of 45 women would be needed to achieve 
80% power in order to detect a difference of -6.0 between the hypothesis mean of 14 and 
the alternate hypotheses mean of 20 with an estimated standard deviation of 14.0 and with 
a significance level (alpha) of 0.05 using a two sided one sample t- test.  
Therefore the sample size needed for a sample of women living with HIV would be 100, 
with 50 women that meet eligibility criteria for antiretroviral therapy and 50 women that 
require AZT prophylaxis. The sample size required for the uninfected women will be 150 
using the correlation to the HIV prevalence of 39%, the correlated HIV uninfected 
pregnant women in KwaZulu- Natal would be 61%. Therefore the total sample size 
required will be 250.   
7. Data collection methods and tools 
Women attending the ANC for the first time are issued an ANC card at that visit.  Relevant 
information is recorded in this card and includes:  
 Demographic data; 
 The date of the first offer of an HIV test;  
 The result of the (rapid) HIV test; 
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 The date and result of the CD4 count; and 
 The initiation date of the appropriate antiretroviral therapy intervention. 
The clinic has a PMTCT register which also captures this information. 
Information related to study variables outlined in section 9 will be captured on the data 
capture sheet by the investigator or a trained field worker (see attached data sheet). Data 
entered onto the data capture sheet from the patient charts will be compared to the PMTCT 
register for confirmation and to add any missing information. 
Data from the data capture sheets will be entered onto an SPSS worksheet for processing and 
analysis. 
8. Statistical planning (variables) 
List of variables for collection: 
 Age 
 Parity 
 Marital status 
 Level of education 
 Gestational age at first ANC visit and number of subsequent antenatal visits 
 Gestational age at which HIV test done in current pregnancy 
 Result of HIV rapid tests 
 Gestational age at which CD4 count taken 
 Gestational age at which CD4 count results received 
 Results of CD4 assays 
 Gestational age at which AZT initiated in those with CD4 counts above 350 cells/ 
mm3 
 Gestational age at which antiretroviral therapy initiated in those with CD4 counts 
below 350 cells/ mm3 
 Gestational age at which (first) diagnosed uninfected 
 Gestational age at which a second HIV test offered and performed 
 Result of second HIV test 
 TB symptom checklist administered in those women living with HIV 
 Outcome of TB symptom checklist 
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 Initiation of antiretroviral therapy occurred at the clinic or referral to local hospital for 
antiretroviral therapy initiation 
 Antiretroviral therapy initiated by nurse or doctor 
9. Measures to improve validity: 
Multiple sources of data collection will be used to verify information collected. The patient file will be the 
primary source of data and the accuracy of this information will be checked against the clinic registers 
and the PMTCT registers. 
10. Measures to reduce bias:  
Selection bias will be overcome by consecutive sampling of all eligible antenatal attendees. 
Information bias will be addressed by training of field workers on use of data collection form and 
understanding of the PMTCT register to extract data. 
11. Data quality, storage and safety  
Multiple sources of data will help improve data quality. 
Once data has been extracted all the data capture sheets will be completed and kept in a locked 
cupboard. Data will be shared among members of the research team and for the purposes of a 
report, otherwise data will be handled as confidential. 
12. Data analysis techniques 
The analytic component of the study will be derived from measuring the data collected against 
the standard of care outlined in National PMTCT Guidelines.  
13. Statistical analysis 
Data capturing and statistical analysis will be performed using SPSS version 18. Descriptive 
statistics specifically the measures of central tendency will be used for all points of the care 
cascade. The mean gestational age, the median CD4 count and median time to antiretroviral 
therapy initiation, the proportion screened for TB and the proportion of HIV uninfected women 
who seroconvert with a seroconversion rate per unit time are some of the statistics that will be 
reported. In addition, a two-sided one sample t-test will be used to test for the analytic 
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component; specifically the lag time to implementation of ART intervention as compared to the 
timelines outlined in the National PMTCT Guidelines.  
14.      Limitations of the study 
14.1 There may be missing data in the patient charts and PMTCT register. This is a limitation of 
using a retrospective chart review. However, by using multiple data sources, minimisation of 
missing data should result. Further laboratory results can be tracked by the investigator on the 
laboratory data management system if necessary.  
14.2 Only one district-level hospital with its referral stream of clinics can be studied which might 
result in selection bias. 
14.3 Antenatal clinics schedule repeat antenatal visits on a specific day of the week. Sampling 
would have to occur on these days and might introduce a bias since these attendees may not 
adhere to appointment days and the sample may then have women who are being managed 
differently.  
15.  Ethical considerations 
No additional harm will result from participation in this study. The routine antenatal data from 
each clinic will be collected and analysed. There will be no immediate benefit to the participants 
of the study; however, there may be an operational systems benefit for future ANC attendees 
depending on the results from the study.  
 
Ethical approval for this study will be sought from the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal. Further permission will be obtained from the national and 
provincial departments of health to conduct the study at the clinics.   
 
16.  Budget:  
The budget will be related to travel costs incurred on travel to the clinics sampled, to the 
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DATA COLLECTION TOOL 
 
CLINIC NAME  
PARTICIPANT INITIALS   
PARTICIPANT IDENTITY NUMBER  
RACE (tick correct option):       Black   Indian 
      Coloured  White  
       Other  
DATE OF BIRTH _______________  AGE (years) ___________ 
PARITY 1           2          3         4  
(circle appropriate number) 
GRAVIDA            1           2          3         4 
(circle appropriate number) 
1st day of LNMP(dd/mmm/yyyy) 
________________ 
EDD     (dd/mmm/yyyy)  
________________ 
MARITAL STATUS (tick correct option):
  
      Single/ widowed 
      Single in stable relationship 
      Married 
      Divorced 
 GESTATIONAL AGE AT FIRST ANC VISIT ____________ weeks          
(dd/mmm/yyyy)__________ 
HIV SPECIFIC INFORMATION: 
1. Agreeable to an HIV test       Yes                                     No 
2.  Result of HIV test          infected                    uninfected 
3. If infected, result of CD4 count       ________cells/ mm3 
4. In those infected, record date for the following:                                            NOT APPLICABLE 
a. HIV infection diagnosed           /                 /            
b. CD4 count taken           /                 /            
c. CD4 count results received at clinic           /                / 
d. HAART initiated            /                 /                              ___________ weeks                                 
5. In women requiring HAART: 
a. Site at which initiation occurred         Clinic                                Referred to hospital 
b. Staff member responsible for initiation          Nurse                               Doctor  
6. In those infected, with regards to TB:  
a. was a TB symptom questionnaire 
administered? 
        Yes                                     No 
If yes 
b. was TB suspected?         Yes                                     No 
c. was the patient referred for 
investigation? 
        Yes                                     No 
7. In those uninfected, record date for the following:                NOT APPLICABLE 
a. HIV status noted           /                 /                          _  __________ weeks                                 
b. Offer of second test           /                 /                            ___________ weeks                                 
c. Result of second test in women who 
tested uninfected at FIRST TEST 
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